A SARS-CoV-2 surrogate virus neutralization test based ACE2â€“spike proteinâ€“protein interaction

Nature Biotechnology

38, 1073-1078

DOI: 10.1038/s41587-020-0631-z

Citation Report

#	Article	IF	Citations
1	The Rapid Coronavirus Antibody Test: Can We Improve Accuracy?. Frontiers in Medicine, 2020, 7, 569.	1.2	12
2	Functionalized TiO2 Nanotube-Based Electrochemical Biosensor for Rapid Detection of SARS-CoV-2. Sensors, 2020, 20, 5871.	2.1	147
3	Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity. Immunity, 2020, 53, 925-933.e4.	6.6	301
4	Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. Cell, 2020, 183, 1024-1042.e21.	13.5	1,195
5	Validation and clinical evaluation of a SARS-CoV-2â€…surrogate virus neutralisation test (sVNT). Emerging Microbes and Infections, 2020, 9, 2394-2403.	3.0	116
6	Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice. Vaccine, 2020, 38, 7205-7212.	1.7	31
7	Cross-reactive memory T cells and herd immunity to SARS-CoV-2. Nature Reviews Immunology, 2020, 20, 709-713.	10.6	229
8	COVID-19 testing and infection surveillance: Is a combined digital contact-tracing and mass-testing solution feasible in the United States?. Cardiovascular Digital Health Journal, 2020, 1, 149-159.	0.5	36
9	Serologic Responses in Healthy Adult with SARS-CoV-2 Reinfection, Hong Kong, August 2020. Emerging Infectious Diseases, 2020, 26, 3076-3078.	2.0	41
10	SARS-CoV-2 in Quarantined Domestic Cats from COVID-19 Households or Close Contacts, Hong Kong, China. Emerging Infectious Diseases, 2020, 26, 3071-3074.	2.0	141
12	Serodiagnostics for Severe Acute Respiratory Syndromeâ€“Related Coronavirus 2. Annals of Internal Medicine, 2020, 173, 450-460.	2.0	124
13	Can Quantitative RT-PCR for SARS-CoV-2 Help in Better Management of Patients and Control of Coronavirus Disease 2019 Pandemic. Indian Journal of Medical Microbiology, 2020, 38, 284-287.	0.3	8
14	A Novel In-Cell ELISA Assay Allows Rapid and Automated Quantification of SARS-CoV-2 to Analyze Neutralizing Antibodies and Antiviral Compounds. Frontiers in Immunology, 2020, 11, 573526.	2.2	31
15	Molecular and Immunological Diagnostic Tests of COVID-19: Current Status and Challenges. IScience, 2020, 23, 101406.	1.9	144
16	SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature, 2020, 584, 457-462.	13.7	1,744
17	Evaluation of Serological Tests for SARS-CoV-2: Implications for Serology Testing in a Low-Prevalence Setting. Journal of Infectious Diseases, 2020, 222, 1280-1288.	1.9	56
18	Virus isolation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for diagnostic and research purposes. Pathology, 2020, 52, 760-763.	0.3	21
19	Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models. Nature Reviews Immunology, 2020, 20, 727-738.	10.6	107

#	Article	IF	Citations
20	Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines. Frontiers in Immunology, 2020, 11, 579250.	2.2	72
21	Understanding the complexities of SARS-CoV2 infection and its immunology: A road to immune-based therapeutics. International Immunopharmacology, 2020, 88, 106980.	1.7	31
22	Detection of the SARS-CoV-2 humanized antibody with paper-based ELISA. Analyst, The, 2020, 145, 7680-7686.	1.7	62
23	Possibility for reverse zoonotic transmission of SARS-CoV-2 to free-ranging wildlife: A case study of bats. PLoS Pathogens, 2020, 16, e1008758.	2.1	127
24	Antibody Responses to SARS-CoV-2: Letâ€™s Stick to Known Knowns. Journal of Immunology, 2020, 205, 2342-2350.	0.4	69
25	Screening for <scp>SARSâ€CoV</scp>â€2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program. Transfusion, 2020, 60, 2938-2951.	0.8	60
26	Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding. MSphere, 2020, 5, .	1.3	62
27	Letter from Singapore: The clinical and research response to COVIDâ€19. Respirology, 2020, 25, 1101-1102.	1.3	10
28	Perspectives on COVID-19 from Singapore: Impact on ESKD Care and Medical Education. Journal of the American Society of Nephrology: JASN, 2020, 31, 2242-2245.	3.0	9
29	Humoral Responses and Serological Assays in SARS-CoV-2 Infections. Frontiers in Immunology, 2020, 11, 610688.	2.2	190
30	SARS-CoV-2 neutralizing antibody levels are correlated with severity of COVID-19 pneumonia. Biomedicine and Pharmacotherapy, 2020, 130, 110629.	2.5	55
31	A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition. Cell Host and Microbe, 2020, 28, 486-496.e6.	5.1	178
32	Low postpandemic wave SARSâ€CoVâ€2 seroprevalence in Kuala Lumpur and Selangor, Malaysia. Journal of Medical Virology, 2021, 93, 647-648.	2.5	19
33	Rapid quantitative screening assay for SARS-CoV-2 neutralizing antibodies using HiBiT-tagged virus-like particles. Journal of Molecular Cell Biology, 2021, 12, 987-990.	1.5	22
34	Coronavirus disease 2019 (COVIDâ€19): An overview of the immunopathology, serological diagnosis and management. Scandinavian Journal of Immunology, 2021, 93, e12998.	1.3	201
35	Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19. Cell, 2021, 184, 169-183.e17.	13.5	580
36	Evaluation of a SARS-CoV-2 Surrogate Virus Neutralization Test for Detection of Antibody in Human, Canine, Cat, and Hamster Sera. Journal of Clinical Microbiology, 2021, 59, .	1.8	102
37	Longitudinal SARS-CoV-2 seroconversion and functional heterogeneity in a pediatric dialysis unit. Kidney International, 2021, 99, 484-486.	2.6	7

#	Article	IF	Citations
38	COVID-19: The Effect of Host Genetic Variations on Hostâ€“Virus Interactions. Journal of Proteome Research, 2021, 20, 139-153.	1.8	14
39	SARS-CoV-2 seroprevalence and transmission risk factors among high-risk close contacts: a retrospective cohort study. Lancet Infectious Diseases, The, 2021, 21, 333-343.	4.6	183
40	Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods. Cellular and Molecular Immunology, 2021, 18, 936-944.	4.8	98
41	<scp>SARSâ€CoVâ€2</scp> neutralization and serology testing of <scp>COVIDâ€19</scp> convalescent plasma from donors with nonsevere disease. Transfusion, 2021, 61, 17-23.	0.8	25
42	Presence, detection, and persistence of SARS-CoV-2 in wastewater and the sustainable remedial measures. , 2021, , 91-114.		2
43	Evaluation of High-Throughput SARS-CoV-2 Serological Assays in a Longitudinal Cohort of Patients with Mild COVID-19: Clinical Sensitivity, Specificity, and Association with Virus Neutralization Test. Clinical Chemistry, 2021, 67, 742-752.	1.5	69
44	Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein. Virology Journal, 2021, 18, 16.	1.4	57
45	Decline in neutralising antibody responses, but sustained Tâ€cell immunity, in COVIDâ€19 patients at 7Âmonths postâ€infection. Clinical and Translational Immunology, 2021, 10, e1319.	1.7	34
46	Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam. SSRN Electronic Journal, 0, , .	0.4	4
48	Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. Journal of Biomedical Science, 2021, 28, 9.	2.6	167
49	Antibodies to SARS-CoV-2 in dogs and cats, USA. Emerging Microbes and Infections, 2021, 10, 1669-1674.	3.0	32
50	A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses. Nature Communications, 2021, 12, 542.	5.8	200
51	Robust correlations across six SARSâ€CoVâ€2 serology assays detecting distinct antibody features. Clinical and Translational Immunology, 2021, 10, e1258.	1.7	28
52	The role of pseudotype neutralization assays in understanding SARS CoV-2. Oxford Open Immunology, 2021, 2, iqab005.	1.2	20
53	Smart materials-integrated sensor technologies for COVID-19 diagnosis. Emergent Materials, 2021, 4, 169-185.	3.2	37
54	Germline IGHV3-53-encoded RBD-targeting neutralizing antibodies are commonly present in the antibody repertoires of COVID-19 patients. Emerging Microbes and Infections, 2021, 10, 1097-1111.	3.0	25
55	Antibody Titers 3-Months Post-Vaccination with the Pfizer/Biontech Vaccine in Greece. SSRN Electronic Journal, 0, , .	0.4	1
56	Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses. Cell Reports Medicine, 2021, 2, 100189.	3.3	149

#	Article	IF	Citations
57	Limited window for donation of convalescent plasma with high live-virus neutralizing antibody titers for COVID-19 immunotherapy. Communications Biology, 2021, 4, 267.	2.0	25
59	Rapid seroconversion and persistent functional IgG antibodies in severe COVID-19 patients correlates with an IL-12p70 and IL-33 signature. Scientific Reports, 2021, 11, 3461.	1.6	30
61	Evidence for SARS-CoV-2 related coronaviruses circulating in bats and pangolins in Southeast Asia. Nature Communications, 2021, 12, 972.	5.8	276
62	COVID-19 Antibody Tests and Their Limitations. ACS Sensors, 2021, 6, 593-612.	4.0	150
63	Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Reports, 2021, 34, 108728.	2.9	568
64	Long-Term Humoral Immune Response in Persons with Asymptomatic or Mild SARS-CoV-2 Infection, Vietnam. Emerging Infectious Diseases, 2021, 27, 663-666.	2.0	14
66	High-level expression of the monomeric SARS-CoV-2 S protein RBD 320-537 in stably transfected CHO cells by the EEF1A1-based plasmid vector. PLoS ONE, 2021, 16, e0242890.	1.1	24
68	Kobophenol A Inhibits Binding of Host ACE2 Receptor with Spike RBD Domain of SARS-CoV-2, a Lead Compound for Blocking COVID-19. Journal of Physical Chemistry Letters, 2021, 12, 1793-1802.	2.1	77
69	Early detection of neutralizing antibodies against SARS-CoV-2 in COVID-19 patients in Thailand. PLoS ONE, 2021, 16, e0246864.	1.1	20
72	SARS Coronavirus-2 Microneutralisation and Commercial Serological Assays Correlated Closely for Some but Not All Enzyme Immunoassays. Viruses, 2021, 13, 247.	1.5	28
73	Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 Sera. MBio, 2021, 12, .	1.8	64
74	A longitudinal study of convalescent plasma (<scp>CCP</scp>) donors and correlation of <scp>ABO</scp> group, initial neutralizing antibodies (<scp>nAb</scp>), and body mass index (<scp>BMI</scp>) with <scp>nAb</scp> and antiâ€nucleocapsid (<scp>NP</scp>) <scp>SARSâ€CoV</scp>â€2 antibody kinetics: Proposals for better quality of <scp>CCP</scp> collections. Transfusion, 2021, 61, 1447-1460.	0.8	22
75	Adaptive immunity to SARS-CoV-2 and COVID-19. Cell, 2021, 184, 861-880.	13.5	1,364
76	Towards Quantitative and Standardized Serological and Neutralization Assays for COVID-19. International Journal of Molecular Sciences, 2021, 22, 2723.	1.8	12
77	Diagnostic Value of IgM and IgG Detection in COVID-19 Diagnosis by the Mobile Laboratory B-LiFE: A Massive Testing Strategy in the Piedmont Region. International Journal of Environmental Research and Public Health, 2021, 18, 3372.	1.2	3
78	Immune Memory in Mild COVID-19 Patients and Unexposed Donors Reveals Persistent T Cell Responses After SARS-CoV-2 Infection. Frontiers in Immunology, 2021, 12, 636768.	2.2	41
79	Detection and Genome Sequencing of SARS-CoV-2 in a Domestic Cat with Respiratory Signs in Switzerland. Viruses, 2021, 13, 496.	1.5	53
81	A homogeneous split-luciferase assay for rapid and sensitive detection of anti-SARS CoV-2 antibodies. Nature Communications, 2021, 12, 1806.	5.8	36

#	Article	IF	Citations
82	DNA vaccine candidate encoding SARS-CoV-2 spike proteins elicited potent humoral and Th1 cell-mediated immune responses in mice. PLoS ONE, 2021, 16, e0248007.	1.1	32
83	SARS-CoV-2 in severe COVID-19 induces a TGF-Î²-dominated chronic immune response that does not target itself. Nature Communications, 2021, 12, 1961.	5.8	145
85	A haemagglutination test for rapid detection of antibodies to SARS-CoV-2. Nature Communications, 2021, 12, 1951.	5.8	54
86	A novel highly quantitative and reproducible assay for the detection of anti-SARS-CoV-2 IgG and IgM antibodies. Scientific Reports, 2021, 11, 5198.	1.6	55
88	Two-tiered SARS-CoV-2 seroconversion screening in the Netherlands and stability of nucleocapsid, spike protein domain 1 and neutralizing antibodies. Infectious Diseases, 2021, 53, 498-512.	1.4	12
89	Persistence of immunoglobulin G after natural infection with SARS-CoV-2. The Cochrane Library, 0, , .	1.5	0
94	Engineering luminescent biosensors for point-of-care SARS-CoV-2 antibody detection. Nature Biotechnology, 2021, 39, 928-935.	9.4	106
98	Correlation of Automated Chemiluminescent Method with Enzyme-Linked Immunosorbent Assay (ELISA) Antibody Titers in Convalescent COVID-19 Plasma Samples: Development of Rapid, Cost-Effective Semi-Quantitative Diagnostic Methods. Journal of Blood Medicine, 2021, Volume 12, 157-164.	0.7	7
99	Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection. Journal of Experimental Medicine, 2021, 218, .	4.2	259
100	A New SARS-CoV-2 Dual-Purpose Serology Test: Highly Accurate Infection Tracing and Neutralizing Antibody Response Detection. Journal of Clinical Microbiology, 2021, 59, .	1.8	110
101	Antibody Responses 8 Months after Asymptomatic or Mild SARS-CoV-2 Infection. Emerging Infectious Diseases, 2021, 27, 928-931.	2.0	104
102	Novel ELISA Protocol Links Pre-Existing SARS-CoV-2 Reactive Antibodies With Endemic Coronavirus Immunity and Age and Reveals Improved Serologic Identification of Acute COVID-19 via Multi-Parameter Detection. Frontiers in Immunology, 2021, 12, 614676.	2.2	13
103	NeutrobodyPlexâ€"monitoring SARSâ€CoVâ€2 neutralizing immune responses using nanobodies. EMBO Reports, 2021, 22, e52325.	2.0	43
105	Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients. Biosensors and Bioelectronics, 2021, 178, 113008.	5.3	21
106	Semicovariance Coefficient Analysis of Spike Proteins from SARS-CoV-2 and Other Coronaviruses for Viral Evolution and Characteristics Associated with Fatality. Entropy, 2021, 23, 512.	1.1	2
107	A Nanoscaffolded Spike-RBD Vaccine Provides Protection against SARS-CoV-2 with Minimal Anti-Scaffold Response. Vaccines, 2021, 9, 431.	2.1	18
108	Serology surveillance of SARS-CoV-2 antibodies among healthcare workers in COVID-19 designated facilities in Malaysia. The Lancet Regional Health - Western Pacific, 2021, 9, 100123.	1.3	12
109	Evaluation of a Commercial Culture-Free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison With an Antireceptor-Binding Domain Enzyme-Linked Immunosorbent Assay. Open Forum Infectious Diseases, 2021, 8, ofab220.	0.4	33

#	Article	IF	Citations
110	A real-time and high-throughput neutralization test based on SARS-CoV-2 pseudovirus containing monomeric infrared fluorescent protein as reporter. Emerging Microbes and Infections, 2021, 10, 894-904.	3.0	16
112	Considerations for bioanalytical characterization and batch release of COVID-19 vaccines. Npj Vaccines, 2021, 6, 53.	2.9	23
114	Evaluation of a commercially-available surrogate virus neutralization test for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Diagnostic Microbiology and Infectious Disease, 2021, 99, 115294.	0.8	80
115	Long-term persistence of RBD+ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection. Cell Reports Medicine, 2021, 2, 100228.	3.3	66
116	Antibody Affinity Governs the Inhibition of SARS-CoV-2 Spike/ACE2 Binding in Patient Serum. ACS Infectious Diseases, 2021, 7, 2362-2369.	1.8	32
117	Sensitive detection of SARS-CoV-2 seroconversion by flow cytometry reveals the presence of nucleoprotein-reactive antibodies in unexposed individuals. Communications Biology, 2021, 4, 486.	2.0	15
118	Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality. Journal of Clinical Investigation, 2021, 131, .	3.9	58
119	Perspective: diagnostic laboratories should urgently develop T cell assays for SARS-CoV-2 infection. Expert Review of Clinical Immunology, 2021, 17, 421-430.	1.3	24
120	Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut, 2021, 70, 1884-1893.	6.1	233
121	SARS-CoV-2 IgG Antibodies Seroprevalence and Sera Neutralizing Activity in MEXICO: A National Cross-Sectional Study during 2020. Microorganisms, 2021, 9, 850.	1.6	19
122	SARS-CoV-2 Serum Neutralization Assay: A Traditional Tool for a Brand-New Virus. Viruses, 2021, 13, 655.	1.5	48
123	A human coronavirus evolves antigenically to escape antibody immunity. PLoS Pathogens, 2021, 17, e1009453.	2.1	183
124	Ageâ€dependent and genderâ€dependent antibody responses against <scp>SARSâ€CoV</scp>â€2 in health workers and octogenarians after vaccination with the <scp>BNT162b2 mRNA</scp> vaccine. American Journal of Hematology, 2021, 96, E257-E259.	2.0	138
125	Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose. Blood, 2021, 137, 3674-3676.	0.6	130
127	Rapid lateral flow tests for the detection of SARS-CoV-2 neutralizing antibodies. Expert Review of Molecular Diagnostics, 2021, 21, 363-370.	1.5	37
128	Comparison of Serological Assays for the Detection of SARS-CoV-2 Antibodies. Viruses, 2021, 13, 713.	1.5	18
129	Analytical and clinical performances of a SARS-CoV-2 S-RBD IgG assay: comparison with neutralization titers. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1444-1452.	1.4	46
133	Prime-boost vaccination of mice and rhesus macaques with two novel adenovirus vectored COVID-19 vaccine candidates. Emerging Microbes and Infections, 2021, 10, 1002-1015.	3.0	22

#	Article	IF	Citations
134	International Forum on the Collection and Use of COVIDâ€19 Convalescent Plasma: Protocols, Challenges and Lessons Learned: Summary. Vox Sanguinis, 2021, 116, 1117-1135.	0.7	7
135	Investigating the Presence of SARS CoV-2 in Free-Living and Captive Animals. Pathogens, 2021, 10, 635.	1.2	32
136	Evaluation of 6 Commercial SARS-CoV-2 Serology Assays Detecting Different Antibodies for Clinical Testing and Serosurveillance. Open Forum Infectious Diseases, 2021, 8, ofab239.	0.4	23
137	One-Stop Serum Assay Identifies COVID-19 Disease Severity and Vaccination Responses. ImmunoHorizons, 2021, 5, 322-335.	0.8	19
139	Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors. Journal of Hematology and Oncology, 2021, 14, 86.	6.9	31
140	Comparison of virus neutralization activity and results of 10 different anti-SARS-CoV-2 serological tests in COVID-19 recovered plasma donors. Practical Laboratory Medicine, 2021, 25, e00222.	0.6	10
142	Review of Current COVID-19 Diagnostics and Opportunities for Further Development. Frontiers in Medicine, 2021, 8, 615099.	1.2	103
143	Early Humoral Responses of Hemodialysis Patients after COVID-19 Vaccination with BNT162b2. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1073-1082.	2.2	88
144	Practical guidance for clinical laboratories for SARS-CoV-2 serology testing. Canada Communicable Disease Report, 2021, 47, 171-183.	0.6	12
145	Dynamics of neutralizing antibody responses to SARS-CoV-2 in patients with COVID-19: an observational study. Signal Transduction and Targeted Therapy, 2021, 6, 197.	7.1	22
146	Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared with healthy controls. Nephrology Dialysis Transplantation, 2021, 36, 1709-1716.	0.4	123
147	Small-Molecule Inhibitors of the Coronavirus Spike: ACE2 Proteinâ€“Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2. ACS Infectious Diseases, 2021, 7, 1519-1534.	1.8	77
148	SARS-CoV-2 S1 NanoBiT: A nanoluciferase complementation-based biosensor to rapidly probe SARS-CoV-2 receptor recognition. Biosensors and Bioelectronics, 2021, 180, 113122.	5.3	21
149	Antibody persistence in the first 6Âmonths following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study. Clinical Microbiology and Infection, 2021, 27, 784.e1-784.e8.	2.8	113
153	International Forum on the Collection and Use of COVIDâ€19 Convalescent Plasma: Responses. Vox Sanguinis, 2021, 116, e71-e120.	0.7	3
154	Use of Lateral Flow Immunoassay to Characterize SARS-CoV-2 RBD-Specific Antibodies and Their Ability to React with the UK, SA and BR P.1 Variant RBDs. Diagnostics, 2021, 11, 1190.	1.3	10
155	COVID-19 mRNA Vaccination Generates Greater Immunoglobulin G Levels in Women Compared to Men. Journal of Infectious Diseases, 2021, 224, 793-797.	1.9	30
157	Early TÂcell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset. Med, 2021, 2, 682-688.e4.	2.2	152

#	Article	IF	Citations
158	Persistence of humoral response upon SARSâ€CoVâ€2 infection. Reviews in Medical Virology, 2022, 32, e2272.	3.9	14
159	Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. Lancet Microbe, The, 2021, 2, e240-e249.	3.4	322
160	A Bioluminescent Biosensor for Quantifying the Interaction of SARS-CoV-2 and Its Receptor ACE2 in Cells and In Vitro. Viruses, 2021, 13, 1055.	1.5	4
161	Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2ÂS for viral entry. Molecular Therapy, 2021, 29, 1984-2000.	3.7	19
162	Tools and Techniques for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)/COVID-19 Detection. Clinical Microbiology Reviews, 2021, 34, .	5.7	205
163	Comparative analysis of antibodies to SARS-CoV-2 between asymptomatic and convalescent patients. IScience, 2021, 24, 102489.	1.9	11
164	Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis. Frontiers in Immunology, 2021, 12, 690698.	2.2	52
165	IMMUNO-COV v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody Titers. MSphere, 2021, 6, e0017021.	1.3	18
166	An ACE2 Triple Decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants. Scientific Reports, 2021, 11, 12740.	1.6	54
168	Advances in Neutralization Assays for SARSâ€CoVâ€2. Scandinavian Journal of Immunology, 2021, 94, e13088.	1.3	40
169	Comparison of two commercial surrogate ELISAs to detect a neutralising antibody response to SARS-CoV-2. Journal of Virological Methods, 2021, 292, 114122.	1.0	30
171	A comparative review of immunoassays for COVID-19 detection. Expert Review of Clinical Immunology, 2021, 17, 573-599.	1.3	74
172	Multianalyte serology in home-sampled blood enables an unbiased assessment of the immune response against SARS-CoV-2. Nature Communications, 2021, 12, 3695.	5.8	32
173	Correlation of sampleâ€toâ€cutâ€off ratio of antiâ€SARSâ€CoVâ€2 IgG antibody chemiluminescent assay with neutralization activity: a prospective multiâ€centric study in India. ISBT Science Series, 2021, , .	1.1	7
174	BNT162b2 mRNA SARS-CoV-2 Vaccine Elicits High Avidity and Neutralizing Antibodies in Healthcare Workers. Vaccines, 2021, 9, 672.	2.1	32
175	Sensitive electrochemical biosensor combined with isothermal amplification for point-of-care COVID-19 tests. Biosensors and Bioelectronics, 2021, 182, 113168.	5.3	75
177	Characterization of neutralizing versus binding antibodies and memory B cells in COVID-19 recovered individuals from India. Virology, 2021, 558, 13-21.	1.1	24
178	Convalescent plasma therapy in patients with moderate-to-severe COVID-19: A study from Indonesia for clinical research in low- and middle-income countries. EClinicalMedicine, 2021, 36, 100931.	3.2	21

#	Article	IF	Citations
179	Evaluation of a Surrogate Enzyme-Linked Immunosorbent Assayâ€“Based Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) cPass Neutralization Antibody Detection Assay and Correlation With Immunoglobulin G Commercial Serology Assays. Archives of Pathology and Laboratory Medicine, 2021, 145, 1212-1220.	1.2	38
180	A SARS-CoV-2 Label-Free Surrogate Virus Neutralization Test and a Longitudinal Study of Antibody Characteristics in COVID-19 Patients. Journal of Clinical Microbiology, 2021, 59, e0019321.	1.8	20
181	SARS-CoV-2 Spike Protein Stabilized in the Closed State Induces Potent Neutralizing Responses. Journal of Virology, 2021, 95, e0020321.	1.5	35
182	Adaptation of the MTT assay for detection of neutralizing antibodies against the SARS-CoV-2 virus. Zhurnal Mikrobiologii Epidemiologii I Immunobiologii, 2021, 98, 253-265.	0.3	10
183	Diagnostic accuracy of three SARS-CoV2 antibody detection assays, neutralizing effect and longevity of serum antibodies. Journal of Virological Methods, 2021, 293, 114173.	1.0	9
186	How to interpret and use COVID-19 serology and immunology tests. Clinical Microbiology and Infection, 2021, 27, 981-986.	2.8	94
187	Immune responses to a single dose of the AZD1222/Covishield vaccine in health care workers. Nature Communications, 2021, 12, 4617.	5.8	44
188	SARS-CoV-2 serology testing: Progress and challenges. Journal of Immunological Methods, 2021, 494, 113060.	0.6	21
189	Fusion Protein of Rotavirus VP6 and SARS-CoV-2 Receptor Binding Domain Induces T Cell Responses. Vaccines, 2021, 9, 733.	2.1	4
190	Intranasal plus subcutaneous prime vaccination with a dual antigen COVID-19 vaccine elicits T-cell and antibody responses in mice. Scientific Reports, 2021, 11, 14917.	1.6	23
192	Serological survey of antibodies against SARSâ€CoVâ€2 in dogs and cats, Thailand. Transboundary and Emerging Diseases, 2022, 69, 2140-2147.	1.3	27
193	Neutralizing Antibodies Titers and Side Effects in Response to BNT162b2 Vaccine in Healthcare Workers with and without Prior SARS-CoV-2 Infection. Vaccines, 2021, 9, 742.	2.1	39
194	Dynamic Assay for Profiling Anti-SARS-CoV-2 Antibodies and Their ACE2/Spike RBD Neutralization Capacity. Viruses, 2021, 13, 1371.	1.5	11
196	SARS-CoV-2 Infection in Dogs and Cats from Southern Germany and Northern Italy during the First Wave of the COVID-19 Pandemic. Viruses, 2021, 13, 1453.	1.5	34
198	SARS-CoV-2 RBD-Tetanus Toxoid Conjugate Vaccine Induces a Strong Neutralizing Immunity in Preclinical Studies. ACS Chemical Biology, 2021, 16, 1223-1233.	1.6	57
199	Humoral immune responses during SARS-CoV-2 mRNA vaccine administration in seropositive and seronegative individuals. BMC Medicine, 2021, 19, 169.	2.3	52
203	Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine. Clinical and Experimental Medicine, 2022, 22, 319-323.	1.9	30
204	A surrogate virus neutralization test to quantify antibody-mediated inhibition of SARS-CoV-2 in finger stick dried blood spot samples. Scientific Reports, 2021, 11, 15321.	1.6	33

#	Article	IF	Citations
206	Chemiluminescence Immunoassay Based Serological Immunoassays for Detection of SARS-CoV-2 Neutralizing Antibodies in COVID-19 Convalescent Patients and Vaccinated Population. Viruses, 2021, 13, 1508.	1.5	12
210	Surviving Older Patients Show Preserved Cellular and Humoral Immunological Memory Several Months After SARS-CoV-2 Infection. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2022, 77, 33-40.	1.7	6
212	A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma. Science Translational Medicine, 2021, 13, .	5.8	68
213	Rapid and Sensitive Inhibitor Screening Using Magnetically Modulated Biosensors. Sensors, 2021, 21, 4814.	2.1	7
215	Antibody Response After Initial Vaccination for SARS-CoV-2 in Patients With Amyloidosis. HemaSphere, 2021, 5, e614.	1.2	7
217	Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2. Viruses, 2021, 13, 1364.	1.5	72
218	Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors. New England Journal of Medicine, 2021, 385, 1401-1406.	13.9	161
219	An electrochemical dual-aptamer biosensor based on metal-organic frameworks MIL-53 decorated with Au@Pt nanoparticles and enzymes for detection of COVID-19 nucleocapsid protein. Electrochimica Acta, 2021, 387, 138553.	2.6	99
220	Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination. Vaccines, 2021, 9, 910.	2.1	50
221	Reply to Schulte-Pelkum, J. Comment on â€œFavresse et al. Persistence of Anti-SARS-CoV-2 Antibodies Depends on the Analytical Kit: A Report for Up to 10 Months after Infection. Microorganisms 2021, 9, 556â€. Microorganisms, 2021, 9, 1849.	1.6	3
222	Firstâ€inâ€Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients With COVIDâ€19. Clinical Pharmacology and Therapeutics, 2021, 110, 1467-1477.	2.3	25
224	Systematic profiling of SARS-CoV-2-specific IgG responses elicited by an inactivated virus vaccine identifies peptides and proteins for predicting vaccination efficacy. Cell Discovery, 2021, 7, 67.	3.1	29
225	Serum antibody response to BNT162b2 after natural SARSâ€CoVâ€2 infection. European Journal of Clinical Investigation, 2021, 51, e13632.	1.7	14
226	A Perspective on the Role of Point-of-Care â€œImmuno-Triagingâ€• to Optimize COVID-19 Vaccination Distribution in a Time of Scarcity. Frontiers in Public Health, 2021, 9, 638316.	1.3	3
227	Performance evaluation of three automated quantitative immunoassays and their correlation with a surrogate virus neutralization test in coronavirus disease 19 patients and preâ€pandemic controls. Journal of Clinical Laboratory Analysis, 2021, 35, e23921.	0.9	51
228	Bat virome research: the past, the present and the future. Current Opinion in Virology, 2021, 49, 68-80.	2.6	17
229	Seroprevalence and SARS-CoV-2 cross-reactivity of endemic coronavirus OC43 and 229E antibodies in Finnish children and adults. Clinical Immunology, 2021, 229, 108782.	1.4	24
230	Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay. JCI Insight, 2021, 6, .	2.3	33

#	Article	IF	Citations
231	One-shot identification of SARS-CoV-2ÂS RBD escape mutants using yeast screening. Cell Reports, 2021, 36, 109627.	2.9	35
232	Heterologous ChAdOx1 nCoV-19/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses among Health Care Workers. Vaccines, 2021, 9, 857.	2.1	49
233	Quantitative SARS-CoV-2 Spike Antibody Response in COVID-19 Patients Using Three Fully Automated Immunoassays and a Surrogate Virus Neutralization Test. Diagnostics, 2021, 11, 1496.	1.3	29
234	Humoral Responses to Single-Dose BNT162b2 mRNA Vaccination in Dialysis Patients Previously Infected With SARS-CoV-2. Frontiers in Medicine, 2021, 8, 721286.	1.2	11
235	Systemic IL-15, IFN-Î³, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients. Cell Reports, 2021, 36, 109504.	2.9	137
236	Drug repurposing against SARS-CoV-2 receptor binding domain using ensemble-based virtual screening and molecular dynamics simulations. Computers in Biology and Medicine, 2021, 135, 104634.	3.9	20
239	Comparison of two assays to detect IgG antibodies to the receptor binding domain of SARSâ€'CoVâ€'2 as a surrogate marker for assessing neutralizing antibodies in COVID-19 patients. International Journal of Infectious Diseases, 2021, 109, 85-89.	1.5	18
240	Influenza Virus-like Particle (VLP) Vaccines Expressing the SARS-CoV-2 S Glycoprotein, S1, or S2 Domains. Vaccines, 2021, 9, 920.	2.1	16
241	SARS-CoV-2 antibodies in the Southern Region of New Zealand, 2020. Pathology, 2021, 53, 645-651.	0.3	8
243	Effective DNA damage response after acute but not chronic immune challenge: SARS-CoV-2 vaccine versus Systemic Lupus Erythematosus. Clinical Immunology, 2021, 229, 108765.	1.4	29
244	SARS-CoV-2 antibody response dynamics and heterogeneous diagnostic performance of four serological tests and a neutralization test in symptomatic healthcare workers with non-severe COVID-19. Journal of Clinical Virology, 2021, 141, 104904.	1.6	5
245	Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany. Emerging Infectious Diseases, 2021, 27, 2174-2178.	2.0	67
247	SARS-CoV-2 Tests: Bridging the Gap between Laboratory Sensors and Clinical Applications. ACS Sensors, 2021, 6, 2815-2837.	4.0	24
249	Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naÃ¯ve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients. BMC Medicine, 2021, 19, 208.	2.3	52
250	One Year on: An Overview of Singaporeâ€™s Response to COVID-19â€"What We Did, How We Fared, How We Can Move Forward. International Journal of Environmental Research and Public Health, 2021, 18, 9125.	1.2	6
251	Durability of antibody response to vaccination and surrogate neutralization of emerging variants based on SARS-CoV-2 exposure history. Scientific Reports, 2021, 11, 17325.	1.6	27
252	The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. Blood Cancer Journal, 2021, 11, 138.	2.8	103
253	Anti-SARS-CoV-2 Antibody Levels Measured by the AdviseDx SARS-CoV-2 Assay Are Concordant with Previously Available Serologic Assays but Are Not Fully Predictive of Sterilizing Immunity. Journal of Clinical Microbiology, 2021, 59, e0098921.	1.8	48

#	Article	IF	Citations
254	Comparison of IgG and neutralizing antibody responses after one or two doses of COVID-19 mRNA vaccine in previously infected and uninfected individuals.. EClinicalMedicine, 2021, 38, 101018.	3.2	77
255	Protective humoral and cellular immune responses to SARS-CoV-2 persist up to 1 year after recovery. Nature Communications, 2021, 12, 4984.	5.8	100
256	Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients. American Journal of Transplantation, 2021, 21, 3980-3989.	2.6	120
257	Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study. Cancers, 2021, 13, 4480.	1.7	44
258	The Impact of Prior Infection and Age on Antibody Persistence After Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine. Clinical Infectious Diseases, 2022, 75, e902-e904.	2.9	18
259	Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study. Blood Advances, 2021, 5, 4398-4405.	2.5	39
260	Impact of Specific N-Glycan Modifications on the Use of Plant-Produced SARS-CoV-2 Antigens in Serological Assays. Frontiers in Plant Science, 2021, 12, 747500.	1.7	8
261	Evaluation of Cell-Based and Surrogate SARS-CoV-2 Neutralization Assays. Journal of Clinical Microbiology, 2021, 59, e0052721.	1.8	71
262	A SARSâ€CoVâ€2 Neutralization Assay using Single Molecule Arrays. Angewandte Chemie, 0, , .	1.6	5
263	Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Regional Health - Europe, The, 2021, 10, 100208.	3.0	446
264	Evaluation of the correlation between the access SARSâ€CoVâ€2 IgM and IgG II antibody tests with the SARSâ€CoVâ€2 surrogate virus neutralization test. Journal of Medical Virology, 2022, 94, 335-341.	2.5	11
265	Dual-Antigen COVID-19 Vaccine Subcutaneous Prime Delivery With Oral Boosts Protects NHP Against SARS-CoV-2 Challenge. Frontiers in Immunology, 2021, 12, 729837.	2.2	18
266	Rapid and Quantitative Detection of Human Antibodies against the 2019 Novel Coronavirus SARS CoV2 and Its Variants as a Result of Vaccination and Infection. Microbiology Spectrum, 2021, 9, e0089021.	1.2	2
267	Detection of SARS-CoV-2 antibodies formed in response to the BNT162b2 and mRNA-1237 mRNA vaccine by commercial antibody tests. Vaccine, 2021, 39, 5563-5570.	1.7	14
268	Antibody response to the first dose of AZD1222 vaccine in COVID-19 convalescent and uninfected individuals in Bangladesh. Expert Review of Vaccines, 2021, 20, 1651-1660.	2.0	13
269	The biological and clinical significance of emerging SARS-CoV-2 variants. Nature Reviews Genetics, 2021, 22, 757-773.	7.7	778
270	A bioluminescent and homogeneous SARS-CoV-2 spike RBD and hACE2 interaction assay for antiviral screening and monitoring patient neutralizing antibody levels. Scientific Reports, 2021, 11, 18428.	1.6	10
271	Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies. Blood Cancer Discovery, 2021, 2, 568-576.	2.6	62

#	Article	IF	Citations
272	Rapid antibody testing for SARS-CoV-2 vaccine response in pediatric healthcare workers. International Journal of Infectious Diseases, 2021, 113, 1-6.	1.5	11
275	Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs. MBio, 2021, 12, e0190821.	1.8	32
278	Analytical and clinical performance of cPass neutralizing antibodies assay. Clinical Biochemistry, 2021, 98, 70-73.	0.8	7
279	Instant determination of the artemisinin from various Artemisia annua L. extracts by LCâ€ESIâ€MS/MS and their inâ€silico modelling and in vitro antiviral activity studies against SARSâ€CoVâ€2. Phytochemical Analysis, 2022, 33, 303-319.	1.2	12
280	Follow-up study on COVID-19 survivors one year after discharge from hospital. International Journal of Infectious Diseases, 2021, 112, 173-182.	1.5	54
281	Semi-quantitative, high throughput analysis of SARS-CoV-2 neutralizing antibodies: Measuring the level and duration of immune response antibodies post infection/vaccination. Vaccine, 2021, 39, 5688-5698.	1.7	10
282	Durable Antibody Responses in Staff at Two Long-Term Care Facilities, during and Post SARS-CoV-2 Outbreaks. Microbiology Spectrum, 2021, 9, e0022421.	1.2	8
283	Competitive ELISA for a serologic test to detect dengue serotype-specific anti-NS1 IgGs using high-affinity UB-DNA aptamers. Scientific Reports, 2021, 11, 18000.	1.6	8
284	Two novel SARS-CoV-2 surrogate virus neutralization assays are suitable for assessing successful immunization with mRNA-1273. Journal of Virological Methods, 2022, 299, 114297.	1.0	25
285	COVIDâ€19 vaccination with BNT162b2 and ChAdOx1 vaccines has the potential to induce nasal neutralizing antibodies. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 304-307.	2.7	3
286	A SARSâ€CoVâ€2 Neutralization Assay Using Single Molecule Arrays. Angewandte Chemie - International Edition, 2021, 60, 25966-25972.	7.2	21
289	Absence of SARS-CoV-2 antibodies in pre-pandemic plasma from children and adults in Vietnam. International Journal of Infectious Diseases, 2021, 111, 127-129.	1.5	7
290	Proteases and variants: context matters for SARS-CoV-2 entry assays. Current Opinion in Virology, 2021, 50, 49-58.	2.6	23
291	Longitudinal evaluation of laboratory-based serological assays for SARS-CoV-2 antibody detection. Pathology, 2021, 53, 773-779.	0.3	7
292	Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians. The Lancet Regional Health - Western Pacific, 2021, 15, 100276.	1.3	22
293	Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Infectious Diseases, The, 2021, 21, 1383-1394.	4.6	82
294	Does poor glycaemic control affect the immunogenicity of the <scp>COVIDâ€19</scp> vaccination in patients with type <scp>2</scp> diabetes: The <scp>CAVEAT</scp> study. Diabetes, Obesity and Metabolism, 2022, 24, 160-165.	2.2	75
295	Comparison of SARS-CoV-2 Antibody Responses and Seroconversion in COVID-19 Patients Using Twelve Commercial Immunoassays. Annals of Laboratory Medicine, 2021, 41, 577-587.	1.2	35

#	Article	IF	Citations
296	Evaluation of a surrogate virus neutralization test for high-throughput serosurveillance of SARS-CoV-2. Journal of Virological Methods, 2021, 297, 114228.	1.0	25
297	Track-etched membrane microplate and smartphone immunosensing for SARS-CoV-2 neutralizing antibody. Biosensors and Bioelectronics, 2021, 192, 113550.	5.3	14
298	A combined strategy to detect plasma samples reliably with high anti-SARS-CoV-2 neutralizing antibody titers in routine laboratories. Journal of Clinical Virology, 2021, 144, 104984.	1.6	7
299	Diagnosis of COVID-19, vitality of emerging technologies and preventive measures. Chemical Engineering Journal, 2021, 423, 130189.	6.6	38
300	An observational study of breakthrough SARS-CoV-2 Delta variant infections among vaccinated healthcare workers in Vietnam. EClinicalMedicine, 2021, 41, 101143.	3.2	78
301	Evaluation of a multi-species SARS-CoV-2 surrogate virus neutralization test. One Health, 2021, 13, 100313.	1.5	28
302	A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trial. The Lancet Regional Health Americas, 2021, 4, 100079.	1.5	27
303	Evidence of neutralizing antibodies against SARS-CoV-2 in domestic cats living with owners with a history of COVID-19 in Lima â€“ Peru. One Health, 2021, 13, 100318.	1.5	15
305	Nature and Dimensions of Systemic Hyperinflammation and its Attenuation by Convalescent Plasma in Severe COVID-19. Journal of Infectious Diseases, 2021, 224, 565-574.	1.9	48
306	Serological investigation of asymptomatic cases of SARS-CoV-2 infection reveals weak and declining antibody responses. Emerging Microbes and Infections, 2021, 10, 905-912.	3.0	16
308	SARS-CoV-2 outbreak in a synagogue community: longevity and strength of anti-SARS-CoV-2 IgG responses. Epidemiology and Infection, 2021, 149, e153.	1.0	0
310	SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness. Scientific Reports, 2021, 11, 2062.	1.6	58
311	Temporal development and neutralising potential of antibodies against SARS-CoV-2 in hospitalised COVID-19 patients: An observational cohort study. PLoS ONE, 2021, 16, e0245382.	1.1	14
313	Correlation between SARSâ€CoVâ€2 antibody screening by immunoassay and neutralizing antibody testing. Transfusion, 2021, 61, 1181-1190.	0.8	42
314	Diagnostic Efficiency of Three Fully Automated Serology Assays and Their Correlation with a Novel Surrogate Virus Neutralization Test in Symptomatic and Asymptomatic SARS-COV-2 Individuals. Microorganisms, 2021, 9, 245.	1.6	33
315	Comprehensive analysis of SARSâ€CoVâ€2 antibody dynamics in New Zealand. Clinical and Translational Immunology, 2021, 10, e1261.	1.7	51
316	Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic. Emerging Microbes and Infections, 2021, 10, 507-535.	3.0	202
317	Methylene Blue Inhibits the SARS-CoV-2 Spikeâ€“ACE2 Protein-Protein Interactionâ€“a Mechanism that can Contribute to its Antiviral Activity Against COVID-19. Frontiers in Pharmacology, 2020, 11, 600372.	1.6	64

#	Article	IF	Citations
318	Diagnostic Value of D-Dimer in COVID-19: A Meta-Analysis and Meta-Regression. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110109.	0.7	87
319	Virusâ€Free and Liveâ€Cell Visualizing SARSâ€CoVâ€2 Cell Entry for Studies of Neutralizing Antibodies and Compound Inhibitors. Small Methods, 2021, 5, 2001031.	4.6	25
320	Serological antibody testing in the COVID-19 pandemic: their molecular basis and applications. Biochemical Society Transactions, 2020, 48, 2851-2863.	1.6	12
321	SARS-CoV-2 Serologic Assays in Control and Unknown Populations Demonstrate the Necessity of Virus Neutralization Testing. Journal of Infectious Diseases, 2021, 223, 1120-1131.	1.9	27
356	Food safety lessons learned from the <scp>COVID</scp>â€19 pandemic. Journal of Food Safety, 2021, 41, e12878.	1.1	34
357	A simple protein-based surrogate neutralization assay for SARS-CoV-2. JCI Insight, 2020, 5, .	2.3	193
358	A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody. PLoS Pathogens, 2020, 16, e1009089.	2.1	55
361	An unusual COVID-19 case with over four months of viral shedding in the presence of low neutralizing antibodies: a case report. Journal of Biomedical Research, 2020, 34, 470.	0.7	8
362	Collaborative networks enable the rapid establishment of serological assays for SARS-CoV-2 during nationwide lockdown in New Zealand. PeerJ, 2020, 8, e9863.	0.9	12
363	Immunology of SARS-CoV-2 infections and vaccines. Advances in Immunology, 2021, 151, 49-97.	1.1	12
364	Bifunctional molecules targeting SARS-CoV-2 spike and the polymeric Ig receptor display neutralization activity and mucosal enrichment. MAbs, 2021, 13, 1987180.	2.6	4
365	Cancer Therapy and Immunogenicity of COVID Vaccine â€“ CANINE Study. SSRN Electronic Journal, 0, , .	0.4	0
366	Rapid development of analytical methods for evaluating pandemic vaccines: a COVID-19 perspective. Bioanalysis, 2021, 13, 1805-1826.	0.6	11
368	The Slower Antibody Response in Myelofibrosis Patients after Two Doses of mRNA SARS-CoV-2 Vaccine Calls for a Third Dose. Biomedicines, 2021, 9, 1480.	1.4	17
369	Evaluation of antibody response after COVIDâ€19 vaccination of healthcare workers. Journal of Medical Virology, 2022, 94, 1060-1066.	2.5	49
370	B and T Cell Responses after a Third Dose of SARS-CoV-2 Vaccine in Kidney Transplant Recipients. Journal of the American Society of Nephrology: JASN, 2021, 32, 3027-3033.	3.0	82
371	Longitudinal Humoral Responses after COVID-19 Vaccination in Peritoneal and Hemodialysis Patients over Twelve Weeks. Vaccines, 2021, 9, 1130.	2.1	36
372	Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors. Vaccines, 2021, 9, 1148.	2.1	10

#	Article	IF	Citations
376	Engineering Extracellular Vesicles Enriched with Palmitoylated ACE2 as COVIDâ€19 Therapy. Advanced Materials, 2021, 33, e2103471.	11.1	60
377	Safety and potency of BIV1â€CovIran inactivated vaccine candidate for SARSâ€CoVâ€2: A preclinical study. Reviews in Medical Virology, 2022, 32, e2305.	3.9	40
378	Surrogate test performance for <scp>SARSâ€CoV</scp>â€2 neutralizing antibodies (<scp>nAbs</scp>) for convalescent plasma (<scp>CCP</scp>): How useful could they be?. Transfusion, 2021, 61, 3455-3467.	0.8	5
379	Head-to-head evaluation of seven different seroassays including direct viral neutralisation in a representative cohort for SARS-CoV-2. Journal of General Virology, 2021, 102, .	1.3	21
384	Waning humoral response 6 months after SARS-CoV-2 vaccination with the mRNA-BNT162b2 vaccine in hemodialysis patients: time for a boost. Kidney International, 2021, 100, 1334-1335.	2.6	42
387	Inhibition of receptorâ€binding domainâ€"ACE2 interaction after two doses of Sinovac's CoronaVac or AstraZeneca/Oxford's AZD1222 SARSâ€CoVâ€2 vaccines. Journal of Medical Virology, 2021, , .	2.5	5
388	Immunogenic T cell epitopes of SARS-CoV-2 are recognized by circulating memory and naÃ¯ve CD8 T cells of unexposed individuals. EBioMedicine, 2021, 72, 103610.	2.7	24
389	The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines. Frontiers in Immunology, 2021, 12, 744887.	2.2	68
390	Sandwich/competitive immuno-sensors on micro-interface for SARS-CoV-2 neutralizing antibodies. Analytica Chimica Acta, 2021, 1187, 339144.	2.6	9
391	A practical approach to SARS-CoV-2 testing in a pre and post-vaccination era. Journal of Clinical Virology Plus, 2021, 1, 100044.	0.4	2
392	Limited and Short-Lasting Virus Neutralizing Titers Induced by Inactivated SARS-CoV-2 Vaccine. Emerging Infectious Diseases, 2021, 27, 3178-3180.	2.0	13
394	Neutralizing Antibodies to SARSâ€CoVâ€2 Selected from a Human Antibody Library Constructed Decades Ago. Advanced Science, 2022, 9, e2102181.	5.6	14
395	Possible harm from glucocorticoid drugs misuse in the early phase of SARS-CoV-2 infection: a narrative review of the evidence. Internal and Emergency Medicine, 2022, 17, 329-338.	1.0	13
396	Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection. EClinicalMedicine, 2021, 41, 101174.	3.2	57
398	A cell-free high throughput assay for assessment of SARS-CoV-2 neutralizing antibodies. New Biotechnology, 2022, 66, 46-52.	2.4	5
399	Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine. Frontiers in Immunology, 2021, 12, 747830.	2.2	69
400	Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins. Scientific Reports, 2021, 11, 21601.	1.6	20
401	Immune Responses to a Single Dose of the AZD1222/Covishield Vaccine at 16 Weeks in Individuals in Sri Lanka. Journal of Immunology, 2021, 207, 2681-2687.	0.4	4

#	Article	IF	Citations
402	Development of a rapid point-of-care test that measures neutralizing antibodies to SARS-CoV-2. Journal of Clinical Virology, 2021, 145, 105024.	1.6	33
403	The way of SARS-CoV-2 vaccine development: success and challenges. Signal Transduction and Targeted Therapy, 2021, 6, 387.	7.1	42
404	Side effects and Immunogenicity following administration of the Sputnik V COVID-19 vaccine in health care workers in Iran. Scientific Reports, 2021, 11, 21464.	1.6	48
405	SARS-CoV-2 mRNA vaccine BNT162b2 triggers a consistent cross-variant humoral and cellular response. Emerging Microbes and Infections, 2021, 10, 2235-2243.	3.0	31
408	Transmission dynamics, clinical characteristics and sero-surveillance in the COVID-19 outbreak in a population dense area of Colombo, Sri Lanka April- May 2020. PLoS ONE, 2021, 16, e0257548.	1.1	8
409	SARS-CoV-2 Serology Testing â€“ A Laboratory Primer. Clinics in Laboratory Medicine, 2021, 42, 1-13.	0.7	0
410	Development and characterization of SARS-CoV-2 variant-neutralizing monoclonal antibodies. Antiviral Research, 2021, 196, 105206.	1.9	1
411	First cases of SARSâ€CoVâ€2 infection in dogs and cats in Thailand. Transboundary and Emerging Diseases, 2022, 69, .	1.3	28
412	SARS-CoV-2 exposure in wild white-tailed deer (Odocoileus virginianus). Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	217
417	Successful Anti-SARS-CoV-2 Spike Protein Antibody Response to Vaccination in MAGT1 Deficiency. Allergy and Rhinology, 2021, 12, 215265672110562.	0.7	3
418	Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2. Clinica Chimica Acta, 2022, 524, 11-17.	0.5	16
419	Murine monoclonal antibodies against RBD of the SARS-CoV-2 spike protein as useful analytical tools for subunit vaccine development and clinical trials. Journal of Immunological Methods, 2022, 500, 113195.	0.6	4
420	Atypical Prolonged Viral Shedding With Intra-Host SARS-CoV-2 Evolution in a Mildly Affected Symptomatic Patient. Frontiers in Medicine, 2021, 8, 760170.	1.2	16
421	Functional Antibodies Against SARS-CoV-2 Receptor Binding Domain Variants with Mutations N501Y or E484K in Human Milk from COVID-19-Vaccinated, -Recovered, and -Unvaccinated Women. Breastfeeding Medicine, 2022, 17, 163-172.	0.8	3
422	Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents. Frontiers in Immunology, 2021, 12, 772240.	2.2	33
423	Neutralization of SARS-CoV-2 Variants in Transplant Recipients After Two and Three Doses of mRNA-1273 Vaccine. Annals of Internal Medicine, 2022, 175, 226-233.	2.0	46
424	Non-propagative human parainfluenza virus type 2 nasal vaccine robustly protects the upper and lower airways against SARS-CoV-2. IScience, 2021, , 103379.	1.9	8
425	Evaluation of Humoral Immune Response after SARS-CoV-2 Vaccination Using Two Binding Antibody Assays and a Neutralizing Antibody Assay. Microbiology Spectrum, 2021, 9, e0120221.	1.2	25

#	Article	IF	Citations
426	Immune response against SARS-CoV-2 variants: the role of neutralization assays. Npj Vaccines, 2021, 6, 142.	2.9	26
427	Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study. Clinical Microbiology and Infection, 2022, 28, 612.e1-612.e7.	2.8	231
428	Nature of Acquired Immune Responses, Epitope Specificity and Resultant Protection from SARS-CoV-2. Journal of Personalized Medicine, 2021, 11, 1253.	1.1	3
429	Effect of BCG Revaccination on Occupationally Exposed Medical Personnel Vaccinated against SARS-CoV-2. Cells, 2021, 10, 3179.	1.8	20
430	Serum Antibody Response Comparison and Adverse Reaction Analysis in Healthcare Workers Vaccinated with the BNT162b2 or ChAdOx1 COVID-19 Vaccine. Vaccines, 2021, 9, 1379.	2.1	12
432	Flexible Plasmonic Biosensors for Healthcare Monitoring: Progress and Prospects. ACS Nano, 2021, 15, 18822-18847.	7.3	78
433	Analysis of longâ€term antibody response in COVIDâ€19 patients by symptoms grade, gender, age, BMI, and medication. Journal of Medical Virology, 2022, 94, 1412-1418.	2.5	16
434	Correlation between Commercial Anti-RBD IgG Titer and Neutralization Titer against SARS-CoV-2 Beta Variant. Diagnostics, 2021, 11, 2216.	1.3	6
437	A rapid simple point-of-care assay for the detection of SARS-CoV-2 neutralizing antibodies. Communications Medicine, 2021, 1, .	1.9	23
441	Short-Term Immunogenicity Profiles and Predictors for Suboptimal Immune Responses in Patients with End-Stage Kidney Disease Immunized with Inactivated SARS-CoV-2 Vaccine. Infectious Diseases and Therapy, 2022, 11, 351-365.	1.8	10
442	Antibody response to SARS-CoV-2 for more than one yearÂâ^'Âkinetics and persistence of detection are predominantly determined by avidity progression and test design. Journal of Clinical Virology, 2022, 146, 105052.	1.6	29
443	Rapid test to assess the escape of SARS-CoV-2 variants of concern. Science Advances, 2021, 7, eabl7682.	4.7	21
444	A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2. EBioMedicine, 2021, 74, 103729.	2.7	29
445	Point-of-care diagnostics: recent developments in a pandemic age. Lab on A Chip, 2021, 21, 4517-4548.	3.1	34
446	Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine. Journal of Korean Medical Science, 2021, 36, e311.	1.1	33
447	Baseline Enrichment of T and NK Cell Genes Predispose to mRNA Vaccine-Associated Systemic Adverse Events that Can Be Alleviated by Altering the Route of Vaccination. SSRN Electronic Journal, 0, , .	0.4	0
448	SARS-CoV-2 Antibody Neutralization Assay Platforms Based on Epitopes Sources: Live Virus, Pseudovirus, and Recombinant S Glycoprotein RBD. Immune Network, 2021, 21, e39.	1.6	3
450	Immunogenicity of Oxford-AstraZeneca COVID-19 Vaccine in Vietnamese Health-Care Workers. American Journal of Tropical Medicine and Hygiene, 2022, 106, 556-561.	0.6	12

#	Article	IF	Citations
451	A COVID-19 vaccine candidate composed of the SARS-CoV-2 RBD dimer and Neisseria meningitidis outer membrane vesicles. RSC Chemical Biology, 2022, 3, 242-249.	2.0	15
452	Neutralizing Activity and SARS-CoV-2 Vaccine mRNA Persistence in Serum and Breastmilk After BNT162b2 Vaccination in Lactating Women. Frontiers in Immunology, 2021, 12, 783975.	2.2	29
453	OUP accepted manuscript. Clinical Chemistry, 2022, , .	1.5	12
454	Immunogenicity of an inactivated SARS-CoV-2 vaccine in people living with HIV-1: a non-randomized cohort study. EClinicalMedicine, 2022, 43, 101226.	3.2	52
455	Dual-detection fluorescent immunochromatographic assay for quantitative detection of SARS-CoV-2 spike RBD-ACE2 blocking neutralizing antibody. Biosensors and Bioelectronics, 2022, 199, 113883.	5.3	21
458	Clinical Utility of Elecsys Anti-SARS-CoV-2 S Assay in COVID-19 Vaccination: An Exploratory Analysis of the mRNA-1273 Phase 1 Trial. Frontiers in Immunology, 2021, 12, 798117.	2.2	42
459	Comparison of the immunogenicity of ChAdOx1 nCoV-19 vaccine against the wild-type and delta variants in kidney transplant recipients and healthy volunteers. American Journal of Transplantation, 2022, 22, 1459-1466.	2.6	9
460	Clinical Application of Antibody Immunity Against SARS-CoV-2: Comprehensive Review on Immunoassay and Immunotherapy. Clinical Reviews in Allergy and Immunology, 2023, 64, 17-32.	2.9	10
461	A new screening system for entry inhibitors based on cell-to-cell transmitted syncytia formation mediated by self-propagating hybrid VEEV-SARS-CoV-2 replicon. Emerging Microbes and Infections, 2022, 11, 465-476.	3.0	4
464	Innate Immune Responses of Vaccinees Determine Early Neutralizing Antibody Production After ChAdOx1nCoV-19 Vaccination. Frontiers in Immunology, 2022, 13, 807454.	2.2	13
465	Monitoring of SARS-CoV-2 Specific Antibodies after Vaccination. Vaccines, 2022, 10, 154.	2.1	8
467	Single-dose SARS-CoV-2 vaccinations with either BNT162b2 or AZD1222 induce disparate Th1 responses and IgA production. BMC Medicine, 2022, 20, 29.	2.3	20
468	Immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 with 12-dose vials: An interim analysis. Vaccine, 2022, 40, 587-593.	1.7	6
469	Development and utilization of a surrogate SARS-CoV-2 viral neutralization assay to assess mRNA vaccine responses. PLoS ONE, 2022, 17, e0262657.	1.1	11
470	Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases. Viruses, 2022, 14, 207.	1.5	27
471	Humoral Immune Response in IBD Patients Three and Six Months after Vaccination with the SARS-CoV-2 mRNA Vaccines mRNA-1273 and BNT162b2. Biomedicines, 2022, 10, 171.	1.4	21
472	Towards a population-based threshold of protection for COVID-19 vaccines. Vaccine, 2022, 40, 306-315.	1.7	107
474	Antibody response to second dose of the BNT162b2 mRNA vaccine in the first 12Âweeks in South Korea: A prospective longitudinal study. Vaccine, 2022, 40, 437-443.	1.7	5

#	Article	IF	Citations
475	Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy. Blood, 2022, 139, 1409-1412.	0.6	28
476	CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity. Blood Cancer Discovery, 2022, 3, 95-102.	2.6	36
477	Previously Unrecognized Nonreproducible Antibodyâ€“Probe Interactions. Analytical Chemistry, 2022, 94, 1974-1982.	3.2	3
479	Finger stick blood test to assess postvaccination <scp>SARSâ€CoV</scp>â€2 neutralizing antibody response against variants. Bioengineering and Translational Medicine, 2022, 7, .	3.9	7
482	An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice. Science Translational Medicine, 2022, 14, .	5.8	57
483	A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19. Nature Communications, 2022, 13, 383.	5.8	39
484	Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients. Med, 2022, 3, 104-118.e4.	2.2	38
485	Kinetics of immune responses to SARS-CoV-2 proteins in individuals with varying severity of infection and following a single dose of the AZD1222. Clinical and Experimental Immunology, 2022, 208, 323-331.	1.1	3
486	Neutralizing antibody activity against the B.1.617.2 (delta) variant 8Âmonths after two-dose vaccination with BNT162b2 in health care workers. Clinical Microbiology and Infection, 2022, 28, 1024.e7-1024.e12.	2.8	15
487	Immune responses following the first dose of the Sputnik V (Gam-COVID-Vac). Scientific Reports, 2022, 12, 1727.	1.6	11
488	Rapid biosensing SARS-CoV-2 antibodies in vaccinated healthy donors. Biosensors and Bioelectronics, 2022, 204, 114054.	5.3	15
490	SARS-CoV-2 Cross-Reactivity in Prepandemic Serum from Rural Malaria-Infected Persons, Cambodia. Emerging Infectious Diseases, 2022, 28, 440-444.	2.0	15
491	WHO international standard for SARS-CoV-2 antibodies to determine markers of protection. Lancet Microbe, The, 2022, 3, e81-e82.	3.4	56
492	Quantifying Neutralizing Antibodies in Patients with COVID-19 by a Two-Variable Generalized Additive Model. MSphere, 2022, 7, e0088321.	1.3	10
493	SARS-CoV-2 prevalence and immunity: a hospital-based study from Malawi. International Journal of Infectious Diseases, 2022, 116, 157-165.	1.5	11
494	A review on evolution of emerging SARS-CoV-2 variants based on spike glycoprotein. International Immunopharmacology, 2022, 105, 108565.	1.7	44
495	Amantadine-assembled nanostimulator enhances dimeric RBD antigen-elicited cross-neutralization against SARS-CoV-2 strains. Nano Today, 2022, 43, 101393.	6.2	2
496	Versatile role of ACE2-based biosensors for detection of SARS-CoV-2 variants and neutralizing antibodies. Biosensors and Bioelectronics, 2022, 203, 114034.	5.3	30

#	Article	IF	Citations
497	Rapid colloidal gold immunochromatographic assay for the detection of SARS-CoV-2 total antibodies after vaccination. Journal of Materials Chemistry B, 2022, 10, 1786-1794.	2.9	21
498	Evaluation of Commercial Anti-SARS-CoV-2 Neutralizing Antibody Assays in Seropositive Subjects. SSRN Electronic Journal, 0, , .	0.4	0
499	Gut microbiota composition is associated with SARS-CoV-2 vaccine immunogenicity and adverse events. Gut, 2022, 71, 1106-1116.	6.1	84
501	RT-PCR negative COVID-19. BMC Infectious Diseases, 2022, 22, 149.	1.3	13
502	An adjuvant strategy enabled by modulation of the physical properties of microbial ligands expands antigen immunogenicity. Cell, 2022, 185, 614-629.e21.	13.5	40
503	Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. Cell, 2022, 185, 896-915.e19.	13.5	189
504	Cutting Edge: Serum but Not Mucosal Antibody Responses Are Associated with Pre-Existing SARS-CoV-2 Spike Cross-Reactive CD4+ T Cells following BNT162b2 Vaccination in the Elderly. Journal of Immunology, 2022, 208, 1001-1005.	0.4	16
505	Fast and Accurate Surrogate Virus Neutralization Test Based on Antibody-Mediated Blocking of the Interaction of ACE2 and SARS-CoV-2 Spike Protein RBD. Diagnostics, 2022, 12, 393.	1.3	5
506	A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity. Vaccine, 2022, 40, 2068-2075.	1.7	17
508	Development of SARS-CoV-2 variant protein microarray for profiling humoral immunity in vaccinated subjects. Biosensors and Bioelectronics, 2022, 204, 114067.	5.3	9
509	Preclinical Immune Response and Safety Evaluation of the Protein Subunit Vaccine Nanocovax for COVID-19. Frontiers in Immunology, 2021, 12, 766112.	2.2	19
511	An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor-binding domain vaccine in aged mice. Science Translational Medicine, 2021, , eabj5305.	5.8	4
512	ChAdOx1 nCoV-19, BNT162b2 and CoronaVac Vaccines Do Not Induce as Strong Neutralising Antibodies with Broad Variant Protection as Infection and Suggest Vaccines that Induce Broader Sterilising Immunity are Essential to Stop the Pandemic. SSRN Electronic Journal, 0, , .	0.4	0
513	Anti-SARS-CoV-2 Neutralizing Antibody Responses after Two Doses of ChAdOx1 nCoV-19 vaccine (AZD1222) in Healthcare Workers. Infection and Chemotherapy, 2022, 54, 140.	1.0	4
514	Inhibitor screening using microarray identifies the high capacity of neutralizing antibodies to Spike variants in SARS-CoV-2 infection and vaccination. Theranostics, 2022, 12, 2519-2534.	4.6	3
517	mRNA COVID-19 vaccine booster fosters B- and T-cell responses in immunocompromised patients. Life Science Alliance, 2022, 5, e202201381.	1.3	29
521	Robust neutralizing antibody response to SARS-CoV-2 mRNA vaccination in adolescents and young adults with childhood-onset rheumatic diseases. Rheumatology, 2022, 61, 4472-4481.	0.9	10
522	Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy. Npj Vaccines, 2022, 7, 28.	2.9	64

#	Article	IF	Citations
523	A method comparison of three immunoassays for detection of neutralizing antibodies against SARSâ€CoVâ€2 receptorâ€binding domain in individuals with adenovirus typeâ€5â€vectored COVIDâ€19 vaccination. Journal of Clinical Laboratory Analysis, 2022, 36, e24306.	0.9	2
524	Non-Invasive Monitoring for Rejection in Kidney Transplant Recipients After SARS-CoV-2 mRNA Vaccination. Frontiers in Immunology, 2022, 13, 838985.	2.2	16
525	Higher SARS-CoV-2 Spike Binding Antibody Levels and Neutralization Capacity 6 Months after Heterologous Vaccination with AZD1222 and BNT162b2. Vaccines, 2022, 10, 322.	2.1	8
526	Enzyme-Linked Immunosorbent Assay: An Adaptable Methodology to Study SARS-CoV-2 Humoral and Cellular Immune Responses. Journal of Clinical Medicine, 2022, 11, 1503.	1.0	4
527	Quantitative Measurement of the SARS-CoV-2 IgG Antibody and Surrogate Neutralizing Antibody Responses among mRNA COVID-19 Vaccine-Inoculated Medical Staff in Designated Medical Institutions for Infectious Diseases. Journal of the Japanese Association for Infectious Diseases, 2022, 96, 52-55.	0.0	1
528	Evaluation of a commercial ELISA as alternative to plaque reduction neutralization test to detect neutralizing antibodies against SARS-CoV-2. Scientific Reports, 2022, 12, 3549.	1.6	34
529	Serological Evidence That SARS-CoV-2 Has Not Emerged in Deer in Germany or Austria during the COVID-19 Pandemic. Microorganisms, 2022, 10, 748.	1.6	19
530	Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial. Vaccine, 2022, 40, 1761-1767.	1.7	12
532	IgG Antibody Response to the Pfizer BNT162b2 SARS-CoV-2 Vaccine in Healthcare Workers with Healthy Weight, Overweight, and Obesity. Vaccines, 2022, 10, 512.	2.1	11
534	The (apparent) antibody paradox in COVID-19. Expert Review of Clinical Immunology, 2022, 18, 335-345.	1.3	9
535	Kinetics of immune responses to the AZD1222/Covishield vaccine with varying dose intervals in Sri Lankan individuals. Immunity, Inflammation and Disease, 2022, 10, e592.	1.3	6
536	Characterization of Serum and Mucosal SARS-CoV-2-Antibodies in HIV-1-Infected Subjects after BNT162b2 mRNA Vaccination or SARS-CoV-2 Infection. Viruses, 2022, 14, 651.	1.5	17
537	Computational studies suggest compounds restoring function of p53 cancer mutants can bind SARS-CoV-2 spike protein. Journal of Biomolecular Structure and Dynamics, 2022, , 1-14.	2.0	0
538	Impaired Neutralizing Antibody Activity against B.1.617.2 (Delta) after Anti-SARS-CoV-2 Vaccination in Patients Receiving Anti-CD20 Therapy. Journal of Clinical Medicine, 2022, 11, 1739.	1.0	6
539	A systematic review and meta-analysis of the accuracy of SARS-COV-2 IGM and IGG tests in individuals with COVID-19. Journal of Clinical Virology, 2022, 148, 105121.	1.6	7
540	Adverse reactions and production of neutralizing anti-SARS-CoV-2 antibodies after ChAdOx1 COVID-19 vaccination: A cross-sectional study in a single center. Journal of Infection and Public Health, 2022, 15, 360-364.	1.9	1
541	Dynamic observation of SARSâ€CoVâ€2 IgM, IgG, and neutralizing antibodies in the development of population immunity through COVIDâ€19 vaccination. Journal of Clinical Laboratory Analysis, 2022, 36, e24325.	0.9	7
542	A rapid bead-based assay for screening of SARS-CoV-2 neutralizing antibodies. Antibody Therapeutics, 2022, 5, 100-110.	1.2	3

#	Article	IF	Citations
543	Inactivated Vaccines Against SARS-CoV-2: Neutralizing Antibody Titers in Vaccine Recipients. Frontiers in Microbiology, 2022, 13, 816778.	1.5	12
544	Coronavirus Resistance Database (CoV-RDB): SARS-CoV-2 susceptibility to monoclonal antibodies, convalescent plasma, and plasma from vaccinated persons. PLoS ONE, 2022, 17, e0261045.	1.1	70
545	Neutralizing Antibody Activity Against the B.1.617.2 (delta) Variant Before and After a Third BNT162b2 Vaccine Dose in Hemodialysis Patients. Frontiers in Immunology, 2022, 13, 840136.	2.2	15
547	Biotechnological Perspectives to Combat the COVID-19 Pandemic: Precise Diagnostics and Inevitable Vaccine Paradigms. Cells, 2022, 11, 1182.	1.8	10
548	Rapid and Quantitative In Vitro Evaluation of SARS-CoV-2 Neutralizing Antibodies and Nanobodies. Analytical Chemistry, 2022, 94, 4504-4512.	3.2	3
549	A cell-based ELISA as surrogate of virus neutralization assay for RBD SARS-CoV-2 specific antibodies. Vaccine, 2022, 40, 1958-1967.	1.7	5
551	Comparative 6-Month Wild-Type and Delta-Variant Antibody Levels and Surrogate Neutralization for Adults Vaccinated with BNT162b2 versus mRNA-1273. Microbiology Spectrum, 2022, 10, e0270221.	1.2	3
552	Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study. Nature Cancer, 2022, 3, 552-564.	5.7	51
553	COVID-19 Breakthrough Infection after Inactivated Vaccine Induced Robust Antibody Responses and Cross-Neutralization of SARS-CoV-2 Variants, but Less Immunity against Omicron. Vaccines, 2022, 10, 391.	2.1	15
554	Low Levels of Neutralizing Antibodies After Natural Infection With Severe Acute Respiratory Syndrome Coronavirus 2 in a Community-Based Serological Study. Open Forum Infectious Diseases, 2022, 9, ofac055.	0.4	4
555	Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseases. Annals of the Rheumatic Diseases, 2022, 81, 881-888.	0.5	33
557	Reduced Immune Response to Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Cohort of Immunocompromised Patients in Chile. Clinical Infectious Diseases, 2022, 75, e594-e602.	2.9	27
558	A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines. Vaccine, 2022, 40, 2551-2560.	1.7	11
559	Persistence of the neutralizing antibody response after SARS-CoV-2 infection. Clinical Microbiology and Infection, 2022, 28, 614.e1-614.e4.	2.8	5
561	Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients. American Journal of Transplantation, 2022, 22, 1873-1883.	2.6	37
562	Frequent Infection of Cats With SARS-CoV-2 Irrespective of Pre-Existing Enzootic Coronavirus Immunity, Brazil 2020. Frontiers in Immunology, 2022, 13, 857322.	2.2	6
564	Systematic profiling of antigen bias in humoral response against SARS-CoV-2. Virus Research, 2022, 312, 198711.	1.1	0
565	Application of the SARS-CoV-2-S1 ACE-2 receptor interaction as the basis of the fully automated assay to detect neutralizing SARS-CoV-2-S1 antibodies in blood samples. Journal of Immunological Methods, 2022, 504, 113258.	0.6	2

#	Article	IF	Citations
566	Performance evaluation of novel fluorescent-based lateral flow immunoassay (LFIA) for rapid detection and quantification of total anti-SARS-CoV-2 S-RBD binding antibodies in infected individuals. International Journal of Infectious Diseases, 2022, 118, 132-137.	1.5	15
567	Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines. EBioMedicine, 2022, 79, 103986.	2.7	23
568	FRET-based hACE2 receptor mimic peptide conjugated nanoprobe for simple detection of SARS-CoV-2. Chemical Engineering Journal, 2022, 442, 136143.	6.6	12
569	Clinical Considerations During Breakthrough Coronavirus Disease 2019 Infections in Vaccinated Individuals With Autoimmunity. Open Forum Infectious Diseases, 2021, 8, ofab577.	0.4	0
570	Detection and Quantification of SARS-CoV-2 Receptor Binding Domain Neutralization by a Sensitive Competitive ELISA Assay. Vaccines, 2021, 9, 1493.	2.1	5
571	Efficacy of anti-SARS-CoV-2 mRNA vaccine in systemic autoimmune disorders: induction of high avidity and neutralising anti-RBD antibodies. RMD Open, 2021, 7, e001914.	1.8	12
573	Antigenic characterization of influenza and SARS-CoV-2 viruses. Analytical and Bioanalytical Chemistry, 2022, 414, 2841-2881.	1.9	11
575	No neutralizing effect of pre-existing tick-borne encephalitis virus antibodies against severe acute respiratory syndrome coronavirus-2: a prospective healthcare worker study. Scientific Reports, 2021, 11, 24198.	1.6	0
576	Differential Antibody Response to Inactivated COVID-19 Vaccines in Healthy Subjects. Frontiers in Cellular and Infection Microbiology, 2021, 11, 791660.	1.8	32
578	Serological Response to SARS-CoV-2 Messenger RNA Vaccine: Real-World Evidence from Italian Adult Population. Vaccines, 2021, 9, 1494.	2.1	9
579	Neutralization of SARS-CoV-2 Variants of Concern in Kidney Transplant Recipients after Standard COVID-19 Vaccination. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 98-106.	2.2	22
581	Recent Developments in SARS-CoV-2 Neutralizing Antibody Detection Methods. Current Medical Science, 2021, 41, 1052-1064.	0.7	16
582	Evaluation of a Rapid Semiquantitative Lateral Flow Assay for the Prediction of Serum Neutralizing Activity Against SARS-CoV-2 Variants. SSRN Electronic Journal, 0, , .	0.4	0
583	Antibody Profiling in COVID-19 Patients with Different Severities by Using Spike Variant Protein Microarrays. Analytical Chemistry, 2022, , .	3.2	7
584	Humoral immune-response to a SARS-CoV-2-BNT162b2 booster in inflammatory arthritis patients who received an inactivated virus vaccine. Annals of the Rheumatic Diseases, 2022, 81, 1338-1340.	0.5	1
585	The Global Impact of COVID-19 on Solid Organ Transplantation: Two Years Into a Pandemic. Transplantation, 2022, 106, 1312-1329.	0.5	44
587	Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays. Frontiers in Cellular and Infection Microbiology, 2022, 12, 822599.	1.8	28
588	Detecting SARS-CoV-2 neutralizing immunity: highlighting the potential of split nanoluciferase technology. Journal of Molecular Cell Biology, 2022, 14, .	1.5	4

#	Article	IF	Citations
589	Dynamics of Neutralizing Antibody and T-Cell Responses to SARS-CoV-2 and Variants of Concern after Primary Immunization with CoronaVac and Booster with BNT162b2 or ChAdOx1 in Health Care Workers. Vaccines, 2022, 10, 639.	2.1	18
590	Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data. Vaccine, 2022, 40, 3203-3209.	1.7	13
591	Performance of Severe Acute Respiratory Syndrome Coronavirus 2 Serological Diagnostic Tests and Antibody Kinetics in Coronavirus Disease 2019 Patients. Frontiers in Microbiology, 2022, 13, 881038.	1.5	2
592	SARS-CoV-2 Cross-Reactivity in Prepandemic Serum from Rural Malaria-Infected Persons, Cambodia. Emerging Infectious Diseases, 2022, 28, 1080-1081.	2.0	1
596	Seroprevalence and dynamics of anti-SARS-CoV-2 antibody among healthcare workers following ChAdOx1 nCoV-19 vaccination. Epidemiology and Infection, 2022, 150, 1-20.	1.0	9
597	Neutralizing antibody and T cell responses to SARS-CoV-2 vaccination in hematopoietic cell transplant recipients. Bone Marrow Transplantation, 2022, 57, 1183-1186.	1.3	6
598	Surrogate neutralization responses following severe acute respiratory syndrome coronavirus 2 vaccination in people with HIV: comparison between inactivated and mRNA vaccine. Aids, 2022, 36, 1255-1264.	1.0	13
599	SARS-CoV-2 Virus-like Particles Produced by a Single Recombinant Baculovirus Generate Anti-S Antibody and Protect against Variant Challenge. Viruses, 2022, 14, 914.	1.5	10
600	Comparison of Six Serological Immunoassays for the Detection of SARS-CoV-2 Neutralizing Antibody Levels in the Vaccinated Population. Viruses, 2022, 14, 946.	1.5	14
601	Development of a rapid neutralizing antibody test for SARS-CoV-2 and its application for neutralizing antibody screening and vaccinated serum testing. , 2022, , .		2
602	SARS-CoV-2 Antibody and T Cell Response after a Third Vaccine Dose in Hemodialysis Patients Compared with Healthy Controls. Vaccines, 2022, 10, 694.	2.1	6
603	Development of a smartphone-based quantum dot lateral flow immunoassay strip for ultrasensitive detection of anti-SARS-CoV-2 IgG and neutralizing antibodies. International Journal of Infectious Diseases, 2022, 121, 58-65.	1.5	19
604	Impaired Humoral Immunity with Concomitant Preserved T Cell Reactivity in IBD Patients on Treatment with Infliximab 6 Month after Vaccination with the SARS-CoV-2 mRNA Vaccine BNT162b2: A Pilot Study. Journal of Personalized Medicine, 2022, 12, 694.	1.1	6
605	Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac. Vaccine, 2022, 40, 3320-3329.	1.7	6
606	Intranasal Delivery of Thermostable Subunit Vaccine for Cross-Reactive Mucosal and Systemic Antibody Responses Against SARS-CoV-2. Frontiers in Immunology, 2022, 13, 858904.	2.2	5
607	Older Adults Mount Less Durable Humoral Responses to Two Doses of COVID-19 mRNA Vaccine but Strong Initial Responses to a Third Dose. Journal of Infectious Diseases, 2022, 226, 983-994.	1.9	26
608	Impaired immune responses in blood cancers improved by third COVID-19 vaccine dose. Nature Cancer, 2022, 3, 534-535.	5.7	1
609	Persistence of immune responses to the Sinopharm/BBIBPâ€CorV vaccine. Immunity, Inflammation and Disease, 2022, 10, .	1.3	20

#	Article	IF	Citations
610	Sensitively detecting antigen of SARS-CoV-2 by NIR-II fluorescent nanoparticles. Nano Research, 2022, 15, 7313-7319.	5.8	17
611	Evaluation of commercial Anti-SARS-CoV-2 neutralizing antibody assays in seropositive subjects. Journal of Clinical Virology, 2022, 152, 105169.	1.6	10
612	Thermodynamically coupled biosensors for detecting neutralizing antibodies against SARS-CoV-2 variants. Nature Biotechnology, 2022, 40, 1336-1340.	9.4	23
613	Behavioralâ€“biological surveillance of emerging infectious diseases among a dynamic cohort in Thailand. BMC Infectious Diseases, 2022, 22, 472.	1.3	0
614	2021 White Paper on Recent Issues in Bioanalysis: TAb/NAb, Viral Vector CDx, Shedding Assays; CRISPR/Cas9 & CAR-T Immunogenicity; PCR & Vaccine Assay Performance; ADA Assay Comparability & Cut Point AppropriatenessÂ(<u>Part 3</u>â€“ Recommendations on Gene Therapy,) Tj ETQq0 0 0 rgBT /Overlock	0.0	1
615	Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine: Interim results of a double-blind, randomised controlled phase 1 and 2 trial. The Lancet Regional Health - Western Pacific, 2022, 24, 100474.	1.3	13
616	Neutralizing activity to SARSâ€CoVâ€2 in 1.2 to 10.0 month convalescent plasma samples of COVIDâ€19: A transversal surrogate in vitro study performed in Quitoâ€Ecuador. Journal of Medical Virology, 2022, , .	2.5	1
617	A Class of Sharkâ€Derived Singleâ€Domain Antibodies can Broadly Neutralize SARSâ€Related Coronaviruses and the Structural Basis of Neutralization and Omicron Escape. Small Methods, 2022, 6, e2200387.	4.6	14
618	SARS-CoV-2 delta variant infection in domestic dogs and cats, Thailand. Scientific Reports, 2022, 12, 8403.	1.6	33
619	Trajectory patterns of SARS-CoV-2 neutralising antibody response in convalescent COVID-19 patients. Communications Medicine, 2022, 2, .	1.9	2
620	A Longitudinal Study of COVID-19 Sequelae and Immunity: Baseline Findings. Annals of Internal Medicine, 2022, 175, 969-979.	2.0	99
624	Harmonization of Multiple SARS-CoV-2 Reference Materials Using the WHO IS (NIBSC 20/136): Results and Implications. Frontiers in Microbiology, 2022, 13, .	1.5	4
627	Immunogenicity and Reactogenicity of mRNA BNT162b2 COVID-19 Vaccine among Thai Adolescents with Chronic Diseases. Vaccines, 2022, 10, 871.	2.1	13
628	A SARSâ€“CoV-2 Spike Receptor Binding Motif Peptide Induces Anti-Spike Antibodies in Mice andIs Recognized by COVID-19 Patients. Frontiers in Immunology, 2022, 13, .	2.2	2
629	Antibody response and seroprevalence in healthcare workers after the BNT162b2 vaccination in a University Hospital at Tokyo. Scientific Reports, 2022, 12, .	1.6	10
630	Longitudinal profile of neutralizing and binding antibodies in vaccinated and convalescent COVIDâ€19 cohorts by chemiluminescent immunoassays. Immunity, Inflammation and Disease, 2022, 10, .	1.3	7
631	Cats and SARS-CoV-2: A Scoping Review. Animals, 2022, 12, 1413.	1.0	17
632	Comparison of Four Systems for SARS-CoV-2 Antibody at Three Time Points after SARS-CoV-2 Vaccination. Diagnostics, 2022, 12, 1349.	1.3	0

#	Article	IF	Citations
633	Adverse effects following antiâ€“COVID-19 vaccination with mRNA-based BNT162b2 are alleviated by altering the route of administration and correlate with baseline enrichment of T and NK cell genes. PLoS Biology, 2022, 20, e3001643.	2.6	22
634	Performance analysis among multiple fully automated anti-SARS-CoV-2 antibody measurement reagents: A potential indicator for the correlation of protection in the antibody titer. Journal of Infection and Chemotherapy, 2022, 28, 1295-1303.	0.8	4
635	The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants. Emerging Microbes and Infections, 2022, 11, 1524-1536.	3.0	39
636	Knowledge, attitudes, and practices associated with zoonotic disease transmission risk in North Sulawesi, Indonesia. One Health Outlook, 2022, 4, .	1.4	3
637	The humoral immune response more than one year after SARS-CoV-2 infection: low detection rate of anti-nucleocapsid antibodies via Euroimmun ELISA. Infection, 2023, 51, 83-90.	2.3	7
638	Longitudinal kinetics of RBD+ antibodies in COVID-19 recovered patients over 14 months. PLoS Pathogens, 2022, 18, e1010569.	2.1	6
639	Development of a Rapid Live SARS-CoV-2 Neutralization Assay Based on a qPCR Readout. Journal of Clinical Microbiology, 2022, 60, .	1.8	4
640	Heterologous prime-boost with the mRNA-1273 vaccine among CoronaVac-vaccinated healthcare workers in Indonesia. Clinical and Experimental Vaccine Research, 2022, 11, 209.	1.1	4
641	Antibody testing as the guide to our living with COVID-19. Japanese Journal of Thrombosis and Hemostasis, 2022, 33, 338-346.	0.1	0
644	Lasting SARS-CoV-2 specific IgG Antibody response in health care workers from Venezuela, 6 months after vaccination with Sputnik V. International Journal of Infectious Diseases, 2022, 122, 850-854.	1.5	6
645	People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose Responses. Journal of Infectious Diseases, 2023, 227, 838-849.	1.9	31
648	Heterogeneity assessment of vaccineâ€induced effects using pointâ€ofâ€care surrogate neutralization test for severe acute respiratory syndrome coronavirus 2. Journal of Clinical Laboratory Analysis, 0, , .	0.9	2
649	Development and Validation of Indirect Enzyme-Linked Immunosorbent Assays for Detecting Antibodies to SARS-CoV-2 in Cattle, Swine, and Chicken. Viruses, 2022, 14, 1358.	1.5	2
650	Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trial. Lancet Respiratory Medicine,the, 2022, 10, 785-795.	5.2	15
651	Characterization of oral and gut microbiome and plasma metabolomics in COVID-19 patients after 1-year follow-up. Military Medical Research, 2022, 9, .	1.9	14
652	Individuals With Weaker Antibody Responses After Booster Immunization Are Prone to Omicron Breakthrough Infections. Frontiers in Immunology, 0, 13, .	2.2	17
653	Inactivated whole-virion vaccine BBV152/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants of concern. Nature Microbiology, 2022, 7, 974-985.	5.9	30
654	IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10 Months After BNT162b2 Vaccination Than After SARS-CoV-2 Infection in Healthcare Workers. Frontiers in Immunology, 0, 13, .	2.2	16

#	Article	IF	Citations
655	Comparison of commercial SARS-CoV-2 surrogate neutralization assays with a full virus endpoint dilution neutralization test in two different cohorts. Journal of Virological Methods, 2022, 307, 114569.	1.0	6
656	Salivary, serological, and cellular immune response to the CoronaVac vaccine in health care workers with or without previous COVID-19. Scientific Reports, 2022, 12, .	1.6	9
657	Coronavirus Disease 2019 Vaccinations in Patients With Chronic Liver Disease and Liver Transplant Recipients: An Update. Frontiers in Medicine, 0, 9, .	1.2	8
658	Cross-Reactivity of IgG Antibodies and Virus Neutralization in mRNA-Vaccinated People Against Wild-Type SARS-CoV-2 and the Five Most Common SARS-CoV-2 Variants of Concern. Frontiers in Immunology, 0, 13, .	2.2	7
659	Vaccination after SARS-CoV-2 infection increased antibody avidity against the Omicron variant compared to vaccination alone. Journal of Infectious Diseases, 0, , .	1.9	1
660	Vaccination of cats with Sad23L-nCoV-S vaccine candidate against major variants of SARS-CoV-2. Molecular Therapy - Methods and Clinical Development, 2022, 26, 181-190.	1.8	2
661	High seroconversion rate and SARS-CoV-2 Delta neutralization in people with HIV vaccinated with BNT162b2. Aids, 2022, 36, 1545-1552.	1.0	10
663	Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2â€“18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 study. Lancet Infectious Diseases, The, 2022, 22, 1303-1312.	4.6	26
664	Characterization of nanoparticles-based vaccines for COVID-19. Nature Nanotechnology, 2022, 17, 570-576.	15.6	64
666	A Randomized Clinical Trial of a Fractional Low Dose of BNT162b2 Booster in Adults Following AZD1222. Vaccines, 2022, 10, 914.	2.1	3
667	Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials. Vaccine, 2022, 40, 4220-4230.	1.7	27
668	Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection. Lancet Infectious Diseases, The, 2022, 22, 943-945.	4.6	31
669	Anti-spike protein antibody responses to BNT162b2 mRNA vaccine: A single-center survey in a COVID-19 non-epidemic area in Japan. Vaccine: X, 2022, 11, 100173.	0.9	1
670	Artificial intelligence-assisted colorimetric lateral flow immunoassay for sensitive and quantitative detection of COVID-19 neutralizing antibody. Biosensors and Bioelectronics, 2022, 213, 114449.	5.3	57
671	Accurate identification of SARS-CoV-2 variant delta using graphene/CRISPR-dCas9 electrochemical biosensor. Talanta, 2022, 249, 123687.	2.9	13
672	A one-year follow-up study on dynamic changes of leukocyte subsets and virus-specific antibodies of patients with COVID-19 in Sichuan, China. International Journal of Medical Sciences, 2022, 19, 1122-1130.	1.1	0
674	Review on In silico Methods, High-throughput Screening Techniques, and Cell Culture Based In Vitro Assays for SARS-CoV-2... Current Medicinal Chemistry, 2022, 29, .	1.2	3
675	Immune Response after 2 Doses of BNT162b2 mRNA COVID-19 Vaccinations in Children and Adolescents with Cancer and Hematologic Diseases. Asian Pacific Journal of Cancer Prevention, 2022, 23, 2049-2055.	0.5	7

#	Article	IF	Citations
676	Cellular Immune Response to BNT162b2 mRNA COVID-19 Vaccine in a Large Cohort of Healthcare Workers in a Tertiary Care University Hospital. Vaccines, 2022, 10, 1031.	2.1	6
678	Serology as a Tool to Assess Infectious Disease Landscapes and Guide Public Health Policy. Pathogens, 2022, 11, 732.	1.2	12
679	Analysis of Interaction Between Odorant Receptors and Flexible Spike of SARS CoV-2- Key to Loss of Smell. Current Neuropharmacology, 2023, 21, 151-159.	1.4	1
680	Neutralizing Antibody Response to Sarbecovirus Is Delayed in Sequential Heterologous Immunization. Viruses, 2022, 14, 1382.	1.5	2
681	mRNA Booster Vaccination Enhances Antibody Responses against SARS-CoV2 Omicron Variant in Individuals Primed with mRNA or Inactivated Virus Vaccines. Vaccines, 2022, 10, 1057.	2.1	11
682	Assessment of neutralizing antibody responses after natural SARS-CoV-2 infection and vaccination in congolese individuals. BMC Infectious Diseases, 2022, 22, .	1.3	6
683	Immunogenicity of BNT162b2 Vaccination against SARS-CoV-2 Omicron Variant and Attitudes toward a COVID-19 Booster Dose among Healthy Thai Adolescents. Vaccines, 2022, 10, 1098.	2.1	4
684	An Updated Review on SARS-CoV-2 Infection in Animals. Viruses, 2022, 14, 1527.	1.5	33
685	Antibody responses to Sinopharm/BBIBP-CorV in pregnant mothers in Sri Lanka. PLOS Global Public Health, 2022, 2, e0000607.	0.5	1
686	Immune responses to Sinopharm/<scp>BBIBPâ€CorV</scp> in individuals in Sri Lanka. Immunology, 2022, 167, 275-285.	2.0	8
687	Durability of Humoral and Cellular Immunity after an Extended Primary Series with Heterologous Inactivated SARS-CoV-2 Prime-Boost and ChAdOx1 nCoV-19 in Dialysis Patients (ICON3). Vaccines, 2022, 10, 1064.	2.1	6
688	Immune response and safety to inactivated COVID-19 vaccine: a comparison between people living with HIV and HIV-naive individuals. AIDS Research and Therapy, 2022, 19, .	0.7	20
689	Homogeneous surrogate virus neutralization assay to rapidly assess neutralization activity of anti-SARS-CoV-2 antibodies. Nature Communications, 2022, 13, .	5.8	14
690	Overview of Neutralization Assays and International Standard for Detecting SARS-CoV-2 Neutralizing Antibody. Viruses, 2022, 14, 1560.	1.5	21
691	Immunity after COVID-19 Recovery and Vaccination: Similarities and Differences. Vaccines, 2022, 10, 1068.	2.1	9
692	Reactogenicity, immunogenicity, and humoral immune response dynamics after the third dose of heterologous COVID-19 vaccines in participants fully vaccinated with inactivated vaccine. Expert Review of Vaccines, 2022, 21, 1873-1881.	2.0	4
693	Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine. Vaccines, 2022, 10, 1071.	2.1	14
694	Comparison of the immunogenicity of five COVIDâ€19 vaccines in Sri Lanka. Immunology, 2022, 167, 263-274.	2.0	12

#	Article	IF	Citations
695	Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults. Vaccine, 2022, 40, 5050-5059.	1.7	9
696	COVID-19 symptom severity predicts neutralizing antibody activity in a community-based serological study. Scientific Reports, 2022, 12, .	1.6	5
697	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulins using chemiluminescence immunoassay and its correlation with neutralizing antibodies. Virus Research, 2022, 319, 198852.	1.1	3
698	SARSâ€CoVâ€2 humoral responses following booster BNT162b2 vaccination in patients with Bâ€cell malignancies. American Journal of Hematology, 2022, 97, 1300-1308.	2.0	12
699	Detection of neutralizing antibodies against multiple SARS-CoV-2 strains in dried blood spots using cell-free PCR. Nature Communications, 2022, 13, .	5.8	8
700	SARS-CoV-2 and Emerging Foodborne Pathogens: Intriguing Commonalities and Obvious Differences. Pathogens, 2022, 11, 837.	1.2	0
702	Strong Correlations between the Binding Antibodies against Wild-Type and Neutralizing Antibodies against Omicron BA.1 and BA.2 Variants of SARS-CoV-2 in Individuals Following Booster (Third-Dose) Vaccination. Diagnostics, 2022, 12, 1781.	1.3	11
703	SARS-CoV-2 Omicron escapes mRNA vaccine booster-induced antibody neutralisation in patients with autoimmune rheumatic diseases: an observational cohort study. Annals of the Rheumatic Diseases, 2022, 81, 1585-1593.	0.5	12
704	Analysis of Factors Affecting Neutralizing Antibody Production after COVID-19 Vaccination Using Newly Developed Rapid Point-of-Care Test. Diagnostics, 2022, 12, 1924.	1.3	6
705	Validation of a Novel Fluorescent Lateral Flow Assay for Rapid Qualitative and Quantitative Assessment of Total Anti-SARS-CoV-2 S-RBD Binding Antibody Units (BAU) from Plasma or Fingerstick Whole-Blood of COVID-19 Vaccinees. Vaccines, 2022, 10, 1318.	2.1	3
707	SARS-CoV-2 antibody progression and neutralizing potential in mild symptomatic COVID-19 patients â€“ a comparative long term post-infection study. Frontiers in Immunology, 0, 13, .	2.2	4
708	Correlation between In Vitro Neutralization Assay and Serological Tests for Protective Antibodies Detection. International Journal of Molecular Sciences, 2022, 23, 9566.	1.8	11
709	SARS-CoV-2 in a Mink Farm in Italy: Case Description, Molecular and Serological Diagnosis by Comparing Different Tests. Viruses, 2022, 14, 1738.	1.5	5
710	Squalene in oil-based adjuvant improves the immunogenicity of SARS-CoV-2 RBD and confirms safety in animal models. PLoS ONE, 2022, 17, e0269823.	1.1	5
711	Humoral response to SARS-CoV-2 mRNA vaccination in previous non-responder kidney transplant recipients after short-term withdrawal of mycophenolic acid. Frontiers in Medicine, 0, 9, .	1.2	10
713	Association Between Human Immunodeficiency Virus Viremia and Compromised Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Beta Variant. Journal of Infectious Diseases, 2023, 227, 211-220.	1.9	6
714	IgM antibodies derived from memory B cells are potent cross-variant neutralizers of SARS-CoV-2. Journal of Experimental Medicine, 2022, 219, .	4.2	15
715	Direct capture of neutralized RBD enables rapid point-of-care assessment of SARS-CoV-2 neutralizing antibody titer. Cell Reports Methods, 2022, 2, 100273.	1.4	5

#	Article	IF	Citations
716	mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant. Communications Biology, 2022, 5, .	2.0	15
717	A strategy to assess spillover risk of bat SARS-related coronaviruses in Southeast Asia. Nature Communications, 2022, 13, .	5.8	31
718	Neutralizing antibody responses in healthcare personnel after three doses of mRNA BNT162b2 vaccine and association with baseline characteristics and past SARS-CoV-2 infection. Vaccine, 2022, 40, 5752-5756.	1.7	5
719	Neutralizing Antibody Response, Safety, and Efficacy of mRNA COVID-19 Vaccines in Pediatric Patients with Inflammatory Bowel Disease: A Prospective Multicenter Caseâ€"Control Study. Vaccines, 2022, 10, 1265.	2.1	6
720	Ultrabright nanoparticle-labeled lateral flow immunoassay for detection of anti-SARS-CoV-2 neutralizing antibodies in human serum. Biomaterials, 2022, 288, 121694.	5.7	15
721	Single-injection COVID-19 subunit vaccine elicits potent immune responses. Acta Biomaterialia, 2022, 151, 491-500.	4.1	3
722	Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose. Nature Communications, 2022, 13, .	5.8	27
723	Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults. Med, 2022, 3, 760-773.e5.	2.2	13
724	Neutralizing antibody responses to SARS-CoV-2: A population based seroepidemiological analysis. Indian Journal of Medical Microbiology, 2022, 40, 585-587.	0.3	3
725	Evaluation of a rapid semiquantitative lateral flow assay for the prediction of serum neutralizing activity against SARS-CoV-2 variants. Journal of Clinical Virology, 2022, 155, 105268.	1.6	2
726	Converting non-neutralizing SARS-CoV-2 antibodies into broad-spectrum inhibitors. Nature Chemical Biology, 2022, 18, 1270-1276.	3.9	8
727	Factors influencing neutralizing antibody titers elicited by coronavirus disease 2019 vaccines. Microbes and Infection, 2023, 25, 105044.	1.0	7
728	Three-Dose Primary Series of Inactivated COVID-19 Vaccine for Persons Living with HIV, Hong Kong. Emerging Infectious Diseases, 2022, 28, 2130-2132.	2.0	5
729	Heterologous Prime-boost of SARS-CoV-2 inactivated vaccine and mRNA BNT162b2 among Healthy Thai Adolescents. Vaccine: X, 2022, 12, 100211.	0.9	4
730	Cross-variant protection against SARS-CoV-2 infection in hamsters immunized with monovalent and bivalent inactivated vaccines. International Journal of Biological Sciences, 2022, 18, 4781-4791.	2.6	5
731	DNA aptamers inhibit SARS-CoV-2 spike-protein binding to hACE2 by an RBD- independent or dependent approach. Theranostics, 2022, 12, 5522-5536.	4.6	13
732	Enhancing Neutralizing Antibodies Against Receptor Binding Domain of SARS-CoV-2 by a Safe Natural Adjuvant System. SSRN Electronic Journal, 0, , .	0.4	0
733	Changes Over Time in COVID-19 Incidence, Vaccinations, Serum Spike IgG, and Viral Neutralizing Potential Among Individuals From a North American Gaming Venue. Journal of Occupational and Environmental Medicine, 2022, 64, 788-796.	0.9	0

#	Article	IF	Citations
734	Analysis of Neutralizing Antibody Levels in Children and Adolescents Up to 16 Months After SARS-CoV-2 Infection. JAMA Pediatrics, 2022, 176, 1142.	3.3	12
735	Neutralizing-antibody response to SARS-CoV-2 for 12 months after the COVID-19 workplace outbreaks in Japan. PLoS ONE, 2022, 17, e0273712.	1.1	4
736	The Association of Baseline Plasma SARS-CoV-2 Nucleocapsid Antigen Level and Outcomes in Patients Hospitalized With COVID-19. Annals of Internal Medicine, 2022, 175, 1401-1410.	2.0	32
737	Technology-assisted adaptive recruitment strategy for a large nation-wide COVID-19 vaccine immunogenicity study in Brunei. Frontiers in Public Health, 0, 10, .	1.3	3
739	Utilization of Receptor-Binding Domain of SARS-CoV-2 Spike Protein ExpressedÂin Escherichia coli for the Development of Neutralizing Antibody Assay. Molecular Biotechnology, 0, , .	1.3	2
740	Impact of hypertension on long-term humoral and cellular response to SARS-CoV-2 infection. Frontiers in Immunology, 0, 13, .	2.2	4
742	Boosting the detection performance of severe acute respiratory syndrome coronavirus 2 test through a sensitive optical biosensor with new superior antibody. Bioengineering and Translational Medicine, 2023, 8, .	3.9	2
743	The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients. Frontiers in Immunology, 0, 13, .	2.2	11
744	Induction of neutralizing antibodies in CLL patients after SARS-CoV-2 mRNA vaccination: a monocentric experience. Clinical and Experimental Medicine, 2023, 23, 1197-1203.	1.9	1
745	A Cellular Assay for Spike/ACE2 Fusion: Quantification of Fusion-Inhibitory Antibodies after COVID-19 and Vaccination. Viruses, 2022, 14, 2118.	1.5	1
746	The neutralization of B.1.617.1 and B.1.1.529 sera from convalescent patients and BBIBP-CorV vaccines. IScience, 2022, 25, 105016.	1.9	2
750	Prospects of animal models and their application in studies on adaptive immunity to SARS-CoV-2. Frontiers in Immunology, 0, 13, .	2.2	4
751	Evaluation of the T cell and B cell response following the administration of COVID-19 vaccines in Korea. Journal of Microbiology, Immunology and Infection, 2022, 55, 1013-1024.	1.5	6
752	Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals. Microbiology Spectrum, 2022, 10, .	1.2	19
753	Therapeutic Role of Neutralizing Antibody for the Treatment against SARS-CoV-2 and Its Emerging Variants: A Clinical and Pre-Clinical Perspective. Vaccines, 2022, 10, 1612.	2.1	14
754	Lower SARS-CoV-2â€“specific humoral immunity in people living with HIV-1 recovered from nonhospitalized COVID-19. JCI Insight, 2022, 7, .	2.3	5
755	Comparative analysis of the neutralizing activity against SARS-CoV-2 Wuhan-Hu-1 strain and variants of concern: Performance evaluation of a pseudovirus-based neutralization assay. Frontiers in Immunology, 0, 13, .	2.2	4
756	Permissive omicron breakthrough infections in individuals with binding or neutralizing antibodies to ancestral SARS-CoV-2. Vaccine, 2022, 40, 5868-5872.	1.7	3

#	Article	IF	Citations
757	Early seasonal coronavirus seroconversion did not produce cross-protective SARS-CoV-2 antibodies. Journal of Infection, 2023, 86, e10-e12.	1.7	2
758	Seroprevalence of SARS-CoV-2 in Mexican Health Care Workers after Two Years of the Pandemic: The Picture of an Ophthalmic Medical Centre. Ophthalmic Epidemiology, 2023, 30, 400-406.	0.8	2
759	Biparatopic nanobodies targeting the receptor binding domain efficiently neutralize SARS-CoV-2. IScience, 2022, 25, 105259.	1.9	4
760	Lessons from the pandemic: Responding to emerging zoonotic viral diseasesâ€"a Keystone Symposia report. Annals of the New York Academy of Sciences, 2022, 1518, 209-225.	1.8	4
761	Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment. Clinical Infectious Diseases, 2023, 76, 573-581.	2.9	29
762	SARS-CoV-2 Omicron variant emerged under immune selection. Nature Microbiology, 2022, 7, 1756-1761.	5.9	21
763	Structural insights for neutralization of Omicron variants BA.1, BA.2, BA.4, and BA.5 by a broadly neutralizing SARS-CoV-2 antibody. Science Advances, 2022, 8, .	4.7	25
764	Evaluating the role of trypsin in silk degumming: An in silico approach. Journal of Biotechnology, 2022, 359, 35-47.	1.9	4
765	Immunogenicity to SARS-CoV-2 Omicron variant among school-aged children with 2-dose of inactivated SARS-CoV-2 vaccines followed by BNT162b2 booster. Vaccine: X, 2022, 12, 100221.	0.9	2
766	Immunogenicity of a Fractional Dose of mRNA BNT162b2 COVID-19 Vaccine for Primary Series and Booster Vaccination among Healthy Adolescents. Vaccines, 2022, 10, 1646.	2.1	4
767	First Detection of the SARS-CoV-2 Omicron BA.5/22B in Monaco. Microorganisms, 2022, 10, 1952.	1.6	2
768	A pseudovirus-based platform to measure neutralizing antibodies in Mexico using SARS-CoV-2 as proof-of-concept. Scientific Reports, 2022, 12, .	1.6	10
769	Estimation of SARS-CoV-2 Neutralizing Activity and Protective Immunity in Different Vaccine Types Using Three Surrogate Virus Neutralization Test Assays and Two Semiquantitative Binding Assays Targeting the Receptor-Binding Domain. Microbiology Spectrum, 2022, 10, .	1.2	3
770	Evaluation of the Efficacy of COVID-19 Booster Vaccinations in Healthcare Personnel. Vaccines, 2022, 10, 1797.	2.1	2
771	Priming conditions shape breadth of neutralizing antibody responses to sarbecoviruses. Nature Communications, 2022, 13, .	5.8	7
772	Comparison of the kinetics and magnitude of antibody responses to different SARS-CoV-2 proteins in Sinopharm/BBIBP-CorV vaccinees following the BNT162b2 booster or natural infection. PLoS ONE, 2022, 17, e0274845.	1.1	3
773	Laboratory assessment of state of post-vaccination humoral immunity to infections with aerosol transmission mechanism. Medical Alphabet, 2022, , 50-54.	0.0	0
774	Artificial Cell Membrane Polymersome-Based Intranasal Beta Spike Formulation as a Second Generation Covid-19 Vaccine. ACS Nano, 2022, 16, 16757-16775.	7.3	11

#	Article	IF	Citations
775	Imprinted antibody responses against SARS-CoV-2 Omicron sublineages. Science, 2022, 378, 619-627.	6.0	117
776	An ELISA Platform for the Quantitative Analysis of SARS-CoV-2 RBD-neutralizing Antibodies As an Alternative to Monitoring of the Virus-Neutralizing Activity. , 2022, 14, 109-119.		2
777	High-Throughput Assay for Identifying Diverse Antagonists of the Binding Interaction between the ACE2 Receptor and the Dynamic Spike Proteins of SARS-CoV-2. ACS Infectious Diseases, 2022, 8, 2259-2270.	1.8	0
778	Outliers Matterâ€"Correlation between S1 IgG SARS-CoV-2 Antibodies and Neutralizing SARS-CoV-2 Antibodies. Microorganisms, 2022, 10, 2067.	1.6	2
779	Immune response induced by novel coronavirus infection. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	8
780	Systemic and Mucosal Humoral Immune Response Induced by Three Doses of the BNT162b2 SARS-CoV-2 mRNA Vaccines. Vaccines, 2022, 10, 1649.	2.1	3
781	Pre-vaccination RT-PCR negative contacts in workplace settings show high, SARS COV-2 neutralizing antibody levels. BMC Public Health, 2022, 22, .	1.2	0
782	Comparison of the safety and immunogenicity of the BNT-162b2 vaccine and the ChAdOx1 vaccine for solid organ transplant recipients: a prospective study. BMC Infectious Diseases, 2022, 22, .	1.3	4
783	Susceptibility to SARS-CoV-2 omicron following ChAdOx1 nCoV-19 and BNT162b2 versus CoronaVac vaccination. IScience, 2022, 25, 105379.	1.9	4
784	Comparison of three different COVID-19 vaccine platforms (CoronaVac, BTN162b2, and Ad5-nCoV) in individuals with and without prior COVID-19: Reactogenicity and neutralizing antibodies. Immunology Letters, 2022, 251-252, 20-28.	1.1	5
785	Reactogenicity and immunogenicity of the intradermal administration of BNT162b2 mRNA vaccine in healthy adults who were primed with an inactivated SARS-CoV-2 vaccine. Vaccine: X, 2022, 12, 100242.	0.9	3
787	Evaluation of commercially available fully automated and ELISA-based assays for detecting anti-SARS-CoV-2 neutralizing antibodies. Scientific Reports, 2022, 12, .	1.6	15
788	BNT162b2 mRNA Vaccineâ€"Induced Immune Response in Oral Fluids and Serum. International Dental Journal, 2023, 73, 435-442.	1.0	3
790	Automated detection of neutralizing SARS-CoV-2 antibodies in minutes using a competitive chemiluminescence immunoassay. Analytical and Bioanalytical Chemistry, 0, , .	1.9	2
791	Persistence of neutralizing antibodies and clinical protection up to 12 months after SARS-CoV-2 infection in elderly. Open Forum Infectious Diseases, 0, , .	0.4	0
792	Determining the SARS-CoV-2 Anti-Spike Cutoff Level Denoting Neutralizing Activity Using Two Commercial Kits. Vaccines, 2022, 10, 1952.	2.1	3
793	SARS-CoV-2 spike RBD-specific IgA and IgG antibodies in breast milk after vaccination with the protein subunit vaccine Abdala. , 2022, 1, 253-261.		1
794	A PEG-lipid-free COVID-19 mRNA vaccine triggers robust immune responses in mice. Materials Horizons, 2023, 10, 466-472.	6.4	4

#	Article	IF	Citations
795	Development of receptor binding domain-based double-antigen sandwich lateral flow immunoassay for the detection and evaluation of SARS-CoV-2 neutralizing antibody in clinical sera samples compared with the conventional virus neutralization test. Talanta, 2023, 255, 124200.	2.9	8
796	A highly sensitive bead-based flow cytometric competitive binding assay to detect SARS-CoV-2 neutralizing antibody activity. Frontiers in Immunology, 0, 13, .	2.2	0
797	Kinetics of Neutralizing Antibodies against Omicron Variant in Vietnamese Healthcare Workers after Primary Immunization with ChAdOx1-S and Booster Immunization with BNT162b2. American Journal of Tropical Medicine and Hygiene, 2022, , .	0.6	1
798	A flow cytometry-based neutralization assay for simultaneous evaluation of blocking antibodies against SARS-CoV-2 variants. Frontiers in Immunology, 0, 13, .	2.2	3
799	Low Spike Antibody Levels and Impaired BA.4/5 Neutralization in Patients with Multiple Myeloma or Waldenstromâ€™s Macroglobulinemia after BNT162b2 Booster Vaccination. Cancers, 2022, 14, 5816.	1.7	14
800	Immunogenicity of COVID-19 vaccines and levels of SARS-CoV-2 neutralising antibody in the Bruneian population: Protocol for a national longitudinal study. BMJ Open, 2022, 12, e067020.	0.8	1
801	An Evaluation of Serological Tests to Determine Postvaccinal Immunity to SARS-CoV-2 by mRNA Vaccines. Journal of Clinical Medicine, 2022, 11, 7534.	1.0	0
802	SARS-CoV-2 Omicron (B.1.1.529) Infection of Wild White-Tailed Deer in New York City. Viruses, 2022, 14, 2770.	1.5	19
803	Antibody Avidity Maturation Following Recovery From Infection or the Booster Vaccination Grants Breadth of SARS-CoV-2 Neutralizing Capacity. Journal of Infectious Diseases, 2023, 227, 780-787.	1.9	10
805	Antibodies Induced by Homologous or Heterologous Inactivated (CoronaVac/BBIBP-CorV) and Recombinant Protein Subunit Vaccines (ZF2001) Dramatically Enhanced Inhibitory Abilities against B.1.351, B.1.617.2, and B.1.1.529 Variants. Vaccines, 2022, 10, 2110.	2.1	2
806	High Heterogeneity of Virus-Neutralizing and RBD-Binding Activities of COVID-19 Convalescent Sera. Molecular Biology, 2022, 56, 1028-1035.	0.4	1
807	Ensemble Modified Aptamer Based Pattern Recognition for Adaptive Target Identification. Nano Letters, 2022, 22, 10057-10065.	4.5	2
810	SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization Test. Life, 2022, 12, 2064.	1.1	0
811	Type of vaccine and immunosuppressive therapy but not diagnosis critically influence antibody response after COVID-19 vaccination in patients with rheumatic disease. RMD Open, 2022, 8, e002650.	1.8	10
812	Antibody response durability following three-dose coronavirus disease 2019 vaccination in people with HIV receiving suppressive antiretroviral therapy. Aids, 2023, 37, 709-721.	1.0	9
813	Relationship between post-vaccination symptoms of Moderna's SARS-CoV-2 vaccine and vaccine-induced anti-spike protein antibody titers in university sports club members. Tenri Medical Bulletin, 2022, 25, 90-97.	0.1	0
814	Performance and correlation of ten commercial immunoassays for the detection of SARS-CoV-2 antibodies. Heliyon, 2022, 8, e12614.	1.4	2
815	Diagnostic performance between in-house and commercial SARS-CoV-2 serological immunoassays including binding-specific antibody and surrogate virus neutralization test (sVNT). Scientific Reports, 2023, 13, .	1.6	5

#	Article	IF	Citations
816	Detection and Molecular Characterization of the SARS-CoV-2 Delta Variant and the Specific Immune Response in Companion Animals in Switzerland. Viruses, 2023, 15, 245.	1.5	7
817	Pilot Study for Immunogenicity of SARS-CoV-2 Vaccine with Seasonal Influenza and Pertussis Vaccines in Pregnant Women. Vaccines, 2023, 11, 119.	2.1	1
818	Comprehensive Comparison of Seven SARS-CoV-2-Specific Surrogate Virus Neutralization and Anti-Spike IgG Antibody Assays Using a Live-Virus Neutralization Assay as a Reference. Microbiology Spectrum, 2023, 11, .	1.2	16
819	SARS-CoV-2 delta (B.1.617.2) spike protein adjuvanted with Alum-3M-052 enhances antibody production and neutralization ability. Frontiers in Public Health, 0, 10, .	1.3	1
820	RBD-Based ELISA and Luminex Predict Anti-SARS-CoV-2 Surrogate-Neutralizing Activity in Two Longitudinal Cohorts of German and Spanish Health Care Workers. Microbiology Spectrum, 2023, 11, .	1.2	1
822	Antibody responses elicited by mRNA vaccination in firefighters persist six months and correlate inversely with age and directly with BMI. Heliyon, 2023, 9, e12746.	1.4	1
824	Validation and Establishment of the SARS-CoV-2 Lentivirus Surrogate Neutralization Assay as a Prescreening Tool for the Plaque Reduction Neutralization Test. Microbiology Spectrum, 2023, 11, .	1.2	6
826	Stable production of recombinant SARS-CoV-2 receptor-binding domain in mammalian cells with co-expression of a fluorescent reporter and its validation as antigenic target for COVID-19 serology testing. Biotechnology Reports (Amsterdam, Netherlands), 2023, 37, e00780.	2.1	3
827	Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants. Npj Vaccines, 2022, 7, .	2.9	19
828	Detection of neutralising antibodies against SARS-CoV-2 in companion animals in Istanbul. Journal of Istanbul Veterinary Sciences, 2022, 6, 128-133.	0.3	0
829	Dissolution-Enhanced Luminescence Enhanced Digital Microfluidics Immunoassay for Sensitive and Automated Detection of H5N1. ACS Applied Materials & Interfaces, 2023, 15, 6526-6535.	4.0	4
830	Performance evaluation of the Ortho VITROS SARS-CoV-2 Spike-Specific Quantitative IgG test by comparison with the surrogate virus neutralizing antibody test and clinical assessment. PLoS ONE, 2023, 18, e0279779.	1.1	2
831	Repeated SARS-CoV-2 vaccination in cancer patients treated with immune checkpoint inhibitors: induction of high-avidity anti-RBD neutralizing antibodies. International Journal of Clinical Oncology, 0, , .	1.0	0
832	A Multivalent and Thermostable Nanobody Neutralizing SARS-CoV-2 Omicron (B.1.1.529). International Journal of Nanomedicine, 0, Volume 18, 353-367.	3.3	10
833	ANTIBODY RESPONSE TO THE COVID-19 VACCINE AMONG PREGNANT WOMEN: A PROSPECTIVE STUDY. Biological & Clinical Sciences Research Journal, 2023, 2023, 191.	0.4	0
834	Clinical efficacy and long-term immunogenicity of an early triple dose regimen of SARS-CoV-2 mRNA vaccination in cancer patients. Annals of the Academy of Medicine, Singapore, 2023, 52, 8-16.	0.2	1
835	Longitudinal efficacy and toxicity of SARS-CoV-2 vaccination in cancer patients treated with immunotherapy. Cell Death and Disease, 2023, 14, .	2.7	4
836	Humoral immune response to inactivated COVID-19 vaccination at the 3rd month among people living with HIV. BMC Infectious Diseases, 2023, 23, .	1.3	4

#	Article	IF	Citations
838	Design of a chimeric ACE-2/Fc-silent fusion protein with ultrahigh affinity and neutralizing capacity for SARS-CoV-2 variants. Antibody Therapeutics, 2023, 6, 59-74.	1.2	0
839	The immunogenicity of an extended dosing interval of BNT162b2 against SARS-CoV-2 Omicron variant among healthy school-aged children, a randomized controlled trial. International Journal of Infectious Diseases, 2023, 130, 52-59.	1.5	2
840	Robust specific RBD responses and neutralizing antibodies after ChAdOx1 nCoV-19 and CoronaVac vaccination in SARS-CoV-2â€“ seropositive individuals. , 2023, 2, 100083.		2
841	Evaluation of residual humoral immune response against SARS-CoV-2 by a surrogate virus neutralization test (sVNT) 9 months after BNT162b2 primary vaccination. Journal of Infection and Chemotherapy, 2023, 29, 624-627.	0.8	1
842	Immunogenic fusion proteins induce neutralizing SARS-CoV-2 antibodies in the serum and milk of sheep. Biotechnology Reports (Amsterdam, Netherlands), 2023, 38, e00791.	2.1	2
843	Development of SARS-CoV-2 neutralizing antibody detection assay by using recombinant plant-produced proteins. Biotechnology Reports (Amsterdam, Netherlands), 2023, 38, e00796.	2.1	2
844	Exposure to diverse sarbecoviruses indicates frequent zoonotic spillover in human communities interacting with wildlife. International Journal of Infectious Diseases, 2023, 131, 57-64.	1.5	8
845	Immune responses to vaccines: from classical to systems approaches. , 2022, , 111-152.		0
846	Evaluation of a biotin-based surrogate virus neutralization test for detecting postvaccination antibodies against SARS-CoV-2 variants in sera. Biochemical and Biophysical Research Communications, 2023, 646, 8-18.	1.0	0
847	Enhancing neutralizing antibodies against receptor binding domain of SARS-CoV-2 by a safe natural adjuvant system. Virus Research, 2023, 326, 199047.	1.1	0
848	Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals. Vaccine, 2023, 41, 1925-1933.	1.7	11
849	Nanocell COVID-19 vaccine triggers a novel immune response pathway producing high-affinity antibodies which neutralize all variants of concern. Frontiers in Immunology, 0, 13, .	2.2	0
850	Diagnostics for Viral Pathogens in Veterinary Diagnostic Laboratories. Veterinary Clinics of North America - Food Animal Practice, 2023, 39, 129-140.	0.5	0
852	Persistence of spike-specific immune responses in BNT162b2-vaccinated donors and generation of rapid ex-vivo T cells expansion protocol for adoptive immunotherapy: A pilot study. Frontiers in Immunology, 0, 14, .	2.2	0
853	Validation of a SARS-CoV-2 Surrogate Virus Neutralization Test in Recovered and Vaccinated Healthcare Workers. Viruses, 2023, 15, 426.	1.5	3
854	Use of the particle agglutination/particle agglutination inhibition test for antigenic analysis of SARSâ€CoVâ€2. Influenza and Other Respiratory Viruses, 2023, 17, .	1.5	0
855	Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine. Open Forum Infectious Diseases, 2023, 10, .	0.4	0
856	Outcomes of vaccinations against respiratory diseases in patients with end-stage renal disease undergoing hemodialysis: A systematic review and meta-analysis. PLoS ONE, 2023, 18, e0281160.	1.1	5

#	Article	IF	Citations
857	Profiling Humoral Immunity After Mixing and Matching COVID-19 Vaccines Using SARS-CoV-2 Variant Protein Microarrays. Molecular and Cellular Proteomics, 2023, 22, 100507.	2.5	4
858	The Impact of Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination and Infection on Neutralizing Antibodies: A Nation-wide Cross-sectional Analysis. Journal of Infectious Diseases, 2023, 227, 1255-1265.	1.9	4
860	Humoral immune response to SARS-CoV-2 mRNA vaccines is associated with choice of vaccine and systemic adverse reactions DMD TNR. Clinical and Experimental Vaccine Research, 2023, 12, 60.	1.1	0
862	SARS-CoV-2 Affects Both Humans and Animals: What Is the Potential Transmission Risk? A Literature Review. Microorganisms, 2023, 11, 514.	1.6	3
863	Assessment of the Interferon-Lambda-3 Polymorphism in the Antibody Response to COVID-19 in Older Adults Seropositive for CMV. Vaccines, 2023, 11, 480.	2.1	0
864	Diagnostic TR-FRET assays for detection of antibodies in patient samples. Cell Reports Methods, 2023, 3, 100421.	1.4	0
865	Low Prevalence of SARS-CoV-2 Antibodies in Canine and Feline Serum Samples Collected during the COVID-19 Pandemic in Hong Kong and Korea. Viruses, 2023, 15, 582.	1.5	2
866	Trajectory of Humoral Responses to Two Doses of ChAdOx1 nCoV-19 Vaccination in Patients Receiving Maintenance Hemodialysis. Microbiology Spectrum, 2023, 11, .	1.2	3
867	Immunogenicity and Safety of the Third Booster Dose with mRNA-1273 COVID-19 Vaccine after Receiving Two Doses of Inactivated or Viral Vector COVID-19 Vaccine. Vaccines, 2023, 11, 553.	2.1	0
870	Comparison of Immunogenicity and Reactogenicity of Five Primary Series of COVID-19 Vaccine Regimens against Circulating SARS-CoV-2 Variants of Concern among Healthy Thai Populations. Vaccines, 2023, 11, 564.	2.1	1
872	Importance, Applications and Features of Assays Measuring SARS-CoV-2 Neutralizing Antibodies. International Journal of Molecular Sciences, 2023, 24, 5352.	1.8	7
873	Relative role of border restrictions, case finding and contact tracing in controlling SARS-CoV-2 in the presence of undetected transmission: a mathematical modelling study. BMC Medicine, 2023, 21, .	2.3	4
875	SARS-Cov-2 Antibody Levels That Confer Immune Protection Based on Neutralization of the Omicron Variant. Transplantation, 0, Publish Ahead of Print, .	0.5	0
876	Genetically engineered pair of cells for serological testing and its application for‹scp›SARSâ€€CoV‹/scp›â€€. Bioengineering and Translational Medicine, 2023, 8, .	3.9	1
877	Response and duration of serum antiâ€€SARSâ€€CoVâ€€ antibodies induced by the third dose of an inactivated vaccine: A prospective longitudinal cohort study at 21 serial time points over 641 days. Journal of Medical Virology, 2023, 95, .	2.5	0
878	Inactivation and spike protein denaturation of novel coronavirus variants by CuxO/TiO2 nano-photocatalysts. Scientific Reports, 2023, 13, .	1.6	3
879	Performance evaluation of newly developed surrogate virus neutralization tests for detecting neutralizing antibodies against SARS-CoV-2. Scientific Reports, 2023, 13, .	1.6	2
880	Antibody Responses Against Emerging SARS-CoV-2 Omicron Lineages After the Fourth Dose of mRNA Vaccine in Kidney Transplant Recipients. Transplantation, 0, Publish Ahead of Print, .	0.5	2

#	Article	IF	Citations
881	Modular adjuvant-free pan-HLA-DR-immunotargeting subunit vaccine against SARS-CoV-2 elicits broad sarbecovirus-neutralizing antibody responses. Cell Reports, 2023, 42, 112391.	2.9	1
882	Circulation of SARS-CoVâ€“Related Coronaviruses and Alphacoronaviruses in Bats from Croatia. Microorganisms, 2023, 11, 959.	1.6	1
883	Comparison of antibody response to coronavirus disease 2019 vaccination between patients with solid or hematologic cancer patients undergoing chemotherapy. Asia-Pacific Journal of Clinical Oncology, 0, , .	0.7	0
884	Immune profiling of SARS-CoV-2 infection during pregnancy reveals NK cell and Î³Î´ T cell perturbations. JCI Insight, 2023, 8, .	2.3	4
885	Rapid engineering of SARS-CoV-2 therapeutic antibodies to increase breadth of neutralization including BQ.1.1, CA.3.1, CH.1.1, XBB.1.16, and XBB.1.5. Antibody Therapeutics, 2023, 6, 108-118.	1.2	1
886	Immunodominant SARSâ€CoVâ€2â€specific CD4⁺ and CD8⁺ Tâ€cell responses elicited by inactivated vaccines in healthy adults. Journal of Medical Virology, 2023, 95, .	2.5	3
890	Diagnostics and analysis of SARS-CoV-2: current status, recent advances, challenges and perspectives. Chemical Science, 2023, 14, 6149-6206.	3.7	12
907	Perinatal Diagnostic of SARS-CoV-2 Infection. , 2023, , 77-89.		0
962	Recent Advancement of Nanostructured Materials for Clinical Challenges in Vaccinology. , 2023, , 135-160.		1
967	Singaporeâ€™s whole-of-nation strategy for pandemic response and vaccination of the population. , 2024, , 87-113.		0
996	The Science of COVID-19. Updates in Clinical Dermatology, 2023, , 1-6.	0.1	0